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PEMETREXED SOM BEHANDLING AV AVANSERT LUNGEKREFT 
Lungekreft er den kreftsykdom som tar flest liv. I Norge er det ca. 2500 nye tilfeller, 
og flere enn 2000 dør årlig av sykdommen. 
Ca. 17 % har småcellet lungekreft. De fleste har god effekt av cellegift- og 
strålebehandling, men de fleste får tilbakefall innen et år.  
Majoriteten av pasienter med lungekreft (> 80 %) har ikke-småcellet 
lungekreft. Godt over halvparten har spredning ved diagnosetidspunktet og tilbys 
livsforlengende cellegiftbehandling. Ulempen med behandlingen er at den kan gi 
plagsomme og i noen tilfeller alvorlige bivirkninger. Mange lungekreftpasienter har 
andre sykdommer - spesielt hjerte-, kar- og lungesykdommer - og det er uvisst om 
disse pasientene tåler cellegiftbehandling like godt som andre. 
Pemetrexed er en relativ ny type cellegift. Bakgrunnen for avhandlingen var 
studier som antydet at medikamentet er effektivt i behandling av begge typer 
lungekreft, og at det muligens gir færre bivirkninger enn andre typer cellegift. 
Målsetningen med avhandlingen var å besvare følgende forskningsspørsmål: 
• Er pemetrexed effektivt og godt tolerert som behandling av tilbakefall av småcellet 
lungekreft? 
• Er pemetrexed pluss carboplatin bedre tolerert og like effektivt som et 
standardregime – gemcitabin pluss carboplatin? 
• Har pasienter med alvorlig, annen sykdom, like god effekt og toleranse for 
cellegiftbehandling som pasienter med bedre generell helse? 
34 pasienter med tilbakefall av småcellet lungekreft ble behandlet med pemetrexed. 
Behandlingen ga lite bivirkninger, men tilbakegang av sykdommen ble kun observert 
hos en pasient. Dette er klart dårligere enn hva man forventer av behandling med 
andre typer cellegift. 
436 pasienter ble inkludert i en fase III studie hvor man sammenlignet 
pemetrexed/ carboplatin mot gemcitabin/carboplatin. Det var ingen forskjell i 
helserelatert livskvalitet eller overlevelse, men pasientene i pemetrexed-armen 
hadde færre bivirkninger. 
Grad av annen sykdom (komorbiditet) ble målt hos 402 av pasientene i fase III 
studien. Det var ingen signifikante forskjeller i overlevelse eller helserelatert 
livskvalitet mellom pasienter med og uten alvorlig komorbiditet, men pasientene med 
alvorlig komorbiditet fikk oftere infeksjoner dersom immunforsvaret ble svekket av 
cellegiftbehandlingen – og alle som døde av slike infeksjoner tilhørte denne gruppen. 
Konklusjonen var likevel at pasienter med alvorlig komorbiditet bør tilbys 
cellegiftbehandling. 
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Background 
Pemetrexed emerged as a new chemotherapeutic agent in the treatment of thoracic 
malignancies in the late 1990s. It was first registered for the treatment of malignant 
pleural mesothelioma and showed promising activity in both non-small cell lung 
cancer (NSCLC) and small-cell lung cancer (SCLC) - with a favorable toxicity-profile. 
Hence, the Norwegian Lung Cancer Study Group initiated studies to investigate the 
efficacy of pemetrexed in recurrent SCLC and to compare pemetrexed plus 
carboplatin with a standard regimen in the first-line treatment of advanced NSCLC. 
Chemotherapy is the standard palliative therapy for most patients with 
advanced NSCLC. Many of these patients have co-existing disorders – due to old 
age or a history of tobacco smoking. Studies have suggested that comorbidity is an 
independent prognostic factor for survival in NSCLC, but it is unclear whether this is 
the case for patients with advanced disease receiving platinum-based chemotherapy 
– and little is known about whether patients with comorbidity have more toxicity or 
deterioration of health related quality of life (HRQoL) from such therapy. 
Consequently, the patients in the NSCLC-study were analyzed for the influence of 
comorbidity on survival, toxicity and HRQoL. 
 
Lung cancer 
Epidemiology 
Lung cancer is one of the most common malignant diseases and the leading cause 
of cancer-deaths worldwide. Approximately 1.4 million cases are diagnosed every 
year, and since the 5-year survival is poor (12-15 %), around 1.2 million die from lung 
cancer annually (Figure 1).1 
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Figure 1 Estimated numbers of new cases (incidence) and deaths (mortality) of the most 
common malignant diseases worldwide in 2002.1 Lung cancer is the most common 
cancer among men and the fifth most common among women. Among men, it is the 
leading cause of cancer deaths, while it is number two on the list among women. 
 
 
 
 
 
In Norway, lung cancer is the third most common cancer (Table 1). In 2007, 2550 
new cases were diagnosed – of whom 1076 were women. The year before, 2007 
patients – including 794 women - died from lung cancer. This means that more 
women die from lung cancer than from breast cancer (n=675).  
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Table 1 The number of new cases of the most common cancers in Norway in 2007 and the 
number of deaths caused by each type of cancer in 2006.2 
 
 
No. Site Incidence 2007 Mortality 2006 
    1 Prostate 4 391 1 042 
2 Breast 2 780 679 
3 Lung cancer (all types) 2 550 2 007 
4 Colon 2 264 1 160 
5 Skin – non-melanoma 1 418 42 
6 Bladder, ureter, urethra 1 287 361 
7 Melanoma 1 192 249 
8 Rectum 1 111 415 
9 CNS 994 280 
10 Non-hodgkin’s lymphoma 797 318 
11 Kidney, renal pelvis 697 238 
12 Pancreas 678 633 
13 Corpus uteri 604 74 
14 Stomach 545 349 
15 Leukemia 515 323 
16 Ovary 449 328 
17 Mouth, pharynx 444 137 
18 Multiple myeloma 320 260 
18 Testis 295 11 
20 Cervix uteri 261 79 
21 Thyroid 218 44 
22 Esophagus 186 177 
23 Soft tissue 152 60 
24 Liver 145 148 
25 Gallbladder, bile ducts 135 62 
26 Hodgkin’s lymphoma 114 9 
27 Mesothelioma 74 60 
28 Bone 45 9 
     Other 1 282 812 
    
 All sites 25 943 10 366 
 
 
 
The incidence of lung cancer is still increasing in Norway, mainly because more and 
more women are diagnosed with the disease (Figure 2).3 Women started smoking 
later than men, and while the proportion of male smokers has declined steadily from 
the 1960s, the number of daily female smokers peaked in the early 1970s and was 
stable until 2000 (Figure 3). Today approximately 21 % of the population are daily 
smokers.4,5 
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Figure 2 The number of new cases of lung cancer per year in Norway from 1953-20073 
 
 
 
 
Figure 3 The proportion of daily smokers in Norway from 1927-20074 
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Etiology 
Before tobacco smoking became popular around 1900, lung cancer was a rare 
disease viewed as “matters of medical curiosity not known to be in any degree 
influenced by medicine and too rare to be of much practical importance”.6 The 
exception was found in areas where exposure to radon caused lung cancer in 60-80 
% of mine workers.7  
Lung cancer accounted for only 1 % of all cancers seen at autopsy in 1878 in 
Dresden, Germany. The percentage had risen to 10 % in 1918 and 14 % in 1927.7 
Several etiologic factors were suggested, but already in 1929 the link between 
tobacco smoking and lung cancer was suspected. Further evidence was provided in 
the 1940-50s,8 but it was not generally accepted that tobacco smoking was the main 
cause of lung cancer (approximately 80-90 % of the cases) until decades later. On 
July 1, 2004, indoor smoking was banned in all public places in Norway. 
Radon, a radioactive gas, is the second major cause of lung cancer 
(approximately 14 % of the cases). Asbestos is the leading cause of malignant 
mesothelioma, but can also cause lung cancer. Other carcinogens are arsenic, nickel 
and chromium.7 Recent reports suggest that cannabis smoking can cause lung 
cancer.9 
Diagnosis and classification 
In Norway, most lung cancers are diagnosed from a sample of the primary tumor 
collected through bronchoscopy. Other methods are CT- or ultrasound-guided per-
cutaneous biopsy or fine-needle aspiration - or surgical resection of the primary 
tumor or a metastasis. The primary analysis is light-microscopy of a tumor sample 
that has undergone standard staining and/or staining by immunohistochemistry. The 
techniques to help classifying tumors have improved over the years, and as a result, 
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the classification system has become more detailed. The current recommendations 
for the classification of malignant lung tumors were published by the World Health 
Organization (WHO) in 2004.10 
The most important distinction is between small-cell (SCLC) and non-small-
cell lung cancer (NSCLC), since these subgroups are treated differently. SCLC is 
sub-classified into small-cell carcinoma (oat cell cancer) and combined small-cell 
carcinoma, but all patients receive the same therapy. There are more subgroups of 
NSCLC (Table 2); the most common are adeno-, squamous cell, large cell and 
adenosquamous carcinomas. Until recently, all patients have received the same 
therapy, but there are now reports suggesting that some agents are more effective in 
specific subsets.11,12 
In some cases, sampling of tissue is not possible or considered to be too risky. 
The diagnosis is then based on the patient’s history of exposure to risk factors, 
clinical features and radiological examination(s). 
Trends in the incidence of subgroups of lung cancer 
Adeno-, squamous cell- and small-cell carcinomas account for 80-90 % of all cases 
of lung cancer, but the incidence of the various subgroups have changed over the 
last 30 years. In recent years, fewer patients develop squamous cell carcinoma or 
small-cell carcinoma, whereas adenocarcinoma is now the most frequent subtype.13 
Worldwide, the incidence of SCLC has fallen to approximately 13 %,13,14 but in 
Norway the proportion has been stable (around 18 %) as late as in 1997-2004 
(personal communication from the Norwegian Cancer Registry, September 2005). 
This means that there are approximately 430 new cases of SCLC annually, which 
makes it the 18th most common cancer in Norway (Table 1). 
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The reasons for the changes in the distribution of subgroups of lung cancer 
are not clear, but the most accepted hypotheses are that this is due to a change in 
the chemical composition of the tobacco-products15 and that filtered cigarettes with 
lower nicotine content lead to deeper inhalation and thereby to exposure of more 
peripheral parts of the lungs to carcinogens;16,17 adenocarcinomas are usually more 
peripherally located than squamous cell and small cell lung cancer.	  
For some reason, less research focuses on SCLC than NSCLC - even though 
SCLC causes approximately 4 % of all cancer deaths and is as common as e.g. 
ovary cancer, myeloma or Hodgkin’s lymphoma – all subject to much research 
activity. Over the last 15 years, the number of publications on NSCLC has increased 
rapidly while the number of publications on SCLC has been stable (Figure 4).18 
 
Figure 4 Numbers of abstracts published for American Society of Clinical Oncology annual 
meetings between 1980 and 2006 for (1) all lung cancer; (2) non-small-cell lung 
cancer; (3) small-cell lung cancer.18 
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Table 2 The latest classification of lung tumors by the World Health Organization (2004). The 
distinction between small-cell and non-small-cell lung cancer is the most important 
since these tumors are treated differently. Adeno-, large cell and squamous cell 
carcinomas are the most common subgroups of non-small cell lung cancer.10 
 
Malignant epithelial tumours Mesenchymal tumours 
Squamous cell carcinoma       Epithelioid haemangioendothelioma  
     Papillary       Angiosarcoma  
     Clear cell       Pleuropulmonary blastoma  
     Small cell       Chondroma  
     Basaloid       Congenial peribronchial myofibroblastic tumour  
      Diffuse pulmonary lymphangiomatosis 
Small cell carcinoma       Inflammatory myofibroblastic tumour  
     Combined small cell carcinoma       Lymphangioleiomyomatosis  
      Synovial sarcoma  
Adenocarcinoma            Monophasic  
     Adenocarcinoma, mixed subtype            Biphasic  
     Acinar adenocarcinoma       Pulmonary artery sarcoma  
     Papillary adenocarcinoma       Pulmonary vein sarcoma  
     Bronchioloalveolar carcinoma   
          Nonmucinous  Benign epithelial tumours 
          Mucinous  Papillomas 
          Mixed nonmucinous and mucinous or 
          indeterminate  
     Squamous cell papilloma  
     Solid adenocarcinoma with mucin production            Exophytic  
          Fetal adenocarcinoma            Inverted  
          Mucinous (“colloid”) carcinoma       Glandular papilloma  
          Mucinous cystadenocarcinoma       Mixed squamous cell and glandular papilloma  
          Signet ring adenocarcinoma  Adenomas 
          Clear cell adenocarcinoma       Alveolar adenoma  
      Papillary adenoma  
Large cell carcinoma       Adenomas of the salivary gland type 
     Large cell neuroendocrine carcinoma            Mucous gland adenoma  
          Combined large cell neuroendocrine carcinoma            Pleomorphic adenoma  
     Basaloid carcinoma            Others 
     Lymphoepithelioma-like carcinoma       Mucinous cystadenoma  
     Clear cell carcinoma   
     Large cell carcinoma with rhabdoid phenotype  Lymphoproliferative tumours 
      Marginal zone B-cell lymphoma of the MALT type  
Adenosquamous carcinoma       Diffuse large B-cell lymphoma  
      Lymphomatoid granulomatosis  
Sarcomatoid carcinoma       Langerhans cell histiocytosis  
     Pleomorphic carcinoma   
     Spindle cell carcinoma  Miscellaneous tumours 
     Giant cell carcinoma      Harmatoma 
     Carcinosarcoma       Sclerosing hemangioma  
     Pulmonary blastoma       Clear cell tumour  
      Germ cell tumours 
Carcinoid tumour            Teratoma, mature  
     Typical carcinoid            Immature  
     Atypical carcinoid            Other germ cell tumours 
      Intrapulmonary thymoma  
Salivary gland tumours Melanoma  
     Mucoepidermoid carcinoma   
     Adenoid cystic carcinoma  Metastatic tumours 
     Epithelial-myoepithelial carcinoma   
  
Preinvasive lesions  
     Squamous carcinoma in situ   
     Atypical adenomatous hyperplasia  
     Diffuse idiopathic pulmonary neuroendocrine cell 
     hyperplasia 
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Staging 
As for cancer patients in general, the extent of disease is the most significant 
prognostic factor in lung cancer – and it is also the most important baseline 
characteristic taken into consideration when recommending therapy (Figure 5).19 
The TNM Classification of Cancer Stage was developed in the 1940s by Dr. 
Denoix at the Institut Gustave-Roussy in France and is used to describe the extent of 
the primary tumor (“T”), lymph node involvement (“N”) and whether distant 
metastases are present (“M”) (Table 3). Based on the TNM-status, the stage of 
disease is then defined (Table 4). The descriptors for T, N and M have changed over 
the years as they have been based on larger and larger databases. The seventh 
edition of the TNM classification has been proposed by the International Association 
for the Study of Lung Cancer (Table 3 & 4)19 and is due to be released in December 
2009 by the UICC – The International Union Against Cancer (www.uicc.org). 
For TNM-staging of lung cancer, a CT scan of the thorax and upper abdomen 
and a clinical investigation including examination of lymph nodes on the neck and in 
the supraclavicular regions is recommended.20 An MRI of the brain and a bone scan 
are routinely conducted when staging SCLC; in NSCLC if metastases to these 
organs are suspected. A PET-CT scan is recommended for all patients eligible for 
surgery since it often reveals more extensive disease than a CT scan alone.21  
SCLC is traditionally divided into limited disease (LD) (approximately 40 % of 
patients14) and extensive disease (ED).22 In LD, all lesions can be included in a 
radiotherapy field – this usually means that they are located within one hemi-thorax 
and the mediastinum. ED-patients have more widespread disease. The rationale for 
dividing between LD and ED, is that concurrent chemoradiotherapy prolongs survival 
when compared with chemotherapy alone,23 but can only be administered to LD-
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patients. For research purposes, a TNM-stage should be defined also for SCLC-
patients, since the definition of LD vs. ED varies. 
Other examinations 
Performance status (Table 5) and weight loss are important prognostic factors.24 
Laboratory testing of hematopoietic-, liver- and renal-function gives an impression of 
overall health status and are necessary for correct dosage of chemotherapy. Heart- 
and lung function tests are often needed to determine whether patients are eligible 
for surgery or curative radiotherapy. 
 
Table 3 Descriptors of TNM for lung cancer (seventh edition of the TNM Classification of 
malignant tumors)19 
 
 
T (Primary tumor) 
 
 
Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in 
sputum or bronchial washings but not visualized by imaging or bronchoscopy 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the 
main bronchus)a 
T1a Tumor ≤ 2 cm in greatest dimension 
T1b Tumor > 2 cm but ≤ 3 cm in greatest dimension 
T2 Tumor > 3 cm but ≤ 7 cm or tumor with any of the following features (T2 tumors with these 
features are classified T2a if ≤ 5 cm): 
• Involves main bronchus, ≥2 cm distal to the carina 
• Invades visceral pleura 
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar 
region but does not involve the entire lung 
T2a Tumor > 3 cm but ≤ 5 cm in greatest dimension 
T2b Tumor > 5 cm but ≤ 7 cm in greatest dimension 
T3 Tumor >7 cm or one that directly invades any of the following: chest wall (including superior 
sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor 
in the main bronchus < 2 cm distal to the carinaa but without involvement of the carina; or 
associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor 
nodule(s) in the same lobe 
T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, 
trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor 
nodule(s) in a different ipsilateral lobe 
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N (Regional lymph nodes) 
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral 
scalene, or supraclavicular lymph node(s) 
 
 
 
M (Distant metastasis) 
 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with 
pleural nodules or malignant pleural (or pericardial) 
effusionb 
M1b Distant metastasis 
 
 
a The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may 
extend proximally to the main bronchus, is also classified as T1. 
b Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic 
examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is non-bloody and is not an exudate. Where these 
elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging 
element and the patient should be classified as T1, T2, T3, or T4. 
 
 
Table 4 Definition of stage of lung cancer based on TNM-status (seventh edition of the TNM 
Classification of malignant tumors)19 
 
 
T/M descriptor              Proposed T/M       N0      N1   N2         N3 
 
T1 (≤ 2 cm) T1a IA IIA IIIA IIIB 
T1 (> 2-3 cm) T1b IA IIA IIIA IIIB 
T2 (≤ 5 cm) T2a IB IIA IIIA IIIB 
T2 (> 5-7 cm) T2b IIA IIB IIIA IIIB 
T2 (> 7) T3 IIB IIIA IIIA IIIB 
T3 invasion  IIB IIIA IIIA IIIB 
T4 (same lobe nodules)  IIB IIIA IIIA IIIB 
T4 (extension) T4 IIIA IIIA IIIB IIIB 
M1 (ipsilateral lung)  IIIA IIIA IIIB IIIB 
T4 (pleural effusion) M1a IV IV IV IV 
M1 (contralateral lung)  IV IV IV IV 
M1 (distant) M1b IV IV IV IV 
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Figure 5 Survival by stage of lung cancer (seventh edition of TNM)19 
 
 
 
Table 5  WHO performance status25 
Grade Definition 
0 Asymptomatic (Fully active, able to carry on all predisease activities without restriction) 
1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature. For example, light 
housework, office work) 
2 Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self care but 
unable to carry out any work activities. Up and about more than 50% of waking hours) 
3 Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined 
to bed or chair 50% or more of waking hours) 
4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or 
chair) 
5 Dead 	  	  	  
The history of the treatment of lung cancer 
The first surgical resection for lung cancer was performed in 1821 by Milton 
Anthony,26 but it was a successful pneumonectomy by dr. Evarts A. Graham in 19336 
that first demonstrated that lung carcinoma was a curable disease. Palliative 
radiotherapy has been used since the 1940s,27 radical radiotherapy on inoperable 
patients was first attempted in the 1950s. Chemotherapy was introduced in 1948,28 
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but the role of chemotherapy was not established until a meta-analysis published in 
1995 showed that such therapy prolonged survival.29 Newer, more effective 
chemotherapeutic agents and conformal radiotherapy were introduced during the 
1990s. The benefit of second-line chemotherapy in SCLC was first demonstrated in 
1989;30 in NSCLC in 200031. In the recent years, a new class of drugs – so-called 
targeted therapy – has been introduced. These compounds are molecules that have 
been designed to block pathways essential for the proliferation of tumor cells. The 
first drug entered clinical practice in 2005 when erlotinib demonstrated prolonged 
survival and improved HRQoL when compared to best supportive care (BSC) alone 
as second-/third-line therapy in NSCLC.12 
 
General recommendations for the treatment of non-
small-cell lung cancer 
All patients with localized or locally advanced disease (stage I – III) are considered 
for surgery. Two studies have demonstrated that adjuvant chemotherapy after radical 
surgical resection improves 5-year survival; from 40.4 % to 44.5 %32 in one study and 
from 54 % to 69 % in another.32,33 
Radical radiotherapy is a treatment option in medically inoperable stage I-II 
patients34 and in stage III (locally advanced disease).35 A Cochrane meta-analysis 
concludes that concurrent radio-/chemotherapy reduces the risk of death when 
compared to radiotherapy alone or sequential chemo-radiotherapy.35 
For patients with more advanced disease, platinum-based two-drug 
combination chemotherapy is the recommended treatment.36 This therapy prolongs 
survival and improves HRQoL.37 Untreated, the median survival is 4-5 months, while 
median survival after chemotherapy is 7-12 months.11,37-40 
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There are indications that adding targeted agents to cytotoxic chemotherapy 
may prolong survival. In one study, the addition of bevacizumab, an anti-angiogenic 
agent, prolonged survival in patients receiving platinum-chemotherapy from 10.3 to 
12.3 months.40 However, a later study failed to confirm this.41 In a recent study, 
patients who received cetuximab in addition to chemotherapy (a monoclonal antibody 
blocking the EGFR-receptor in tumor cells) had a longer survival than the patients 
who received chemotherapy alone (11.3 vs. 10.3 months; p=.044).42 
  Second-line chemotherapy and erlotinib are superior to best supportive care 
alone in recurrent disease.12,31 Palliative radiotherapy is a treatment option for brain 
metastases, tumor compression of vital structures, ulcers and painful lesions. 
 
Palliative chemotherapy as first-line treatment of 
advanced NSCLC 
The first report on the use of chemotherapy in inoperable lung cancer was published 
in 1948 by Karnofsky et al.28 Of 35 patients, 74 % had symptom improvement and 49 
% had objective improvement from one course of methyl-bis (ß-chloroethyl) amine 
hydrochloride. However, the duration of response was short – from two weeks to two 
months. 
The first randomized trial comparing two chemotherapeutic agents in the 
treatment of cancer was published in 1960 by Zubrod et al.43 In this study, 258 
patients with breast (n=76) and lung cancer (n=132), malignant melanoma (n=30) 
and Hodgkin’s disease (n=20) were randomized to receive either nitrogen mustard or 
triethylene thiophosphamide. Among the lung cancer patients, there was a higher 
objective response-rate, but not significantly longer survival for the nitrogen mustard 
therapy. 
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The first evidence of the cytotoxic properties of cisplatin was published in 
1969.44 The first human studies demonstrating activity were conducted in the early 
1970s,45,46 and later studies demonstrated response rates of 20-30 % in NSCLC.47-49 
Several other compounds showed single-agent activity in NSCLC in the same era; 
cyclophosphamide, etoposide, vinblastine, vindesine, doxorubicin and methotrexate. 
Soon, studies comparing the efficacy of combination chemotherapy with 
monotherapy were conducted. Doublets improved response rates, but not survival - 
and no standard was defined until a meta-analysis was published by the Non-Small-
Cell Lung Cancer Collaborative Group in 1995.29 In this study, which established the 
use of chemotherapy in NSCLC, cisplatin-containing regimens were found to be 
superior to no chemotherapy in all patient-categories. In advanced disease, a hazard 
ratio of .73 in favor of chemotherapy over best supportive care alone was estimated; 
equivalent to an improvement of 1-year survival of 10 % or an increased median 
survival of 1.5 months. An updated meta-analysis published in 2008 confirmed the 
survival benefit of chemotherapy over BSC alone and estimated a prolongation of 
median OS from 4.5 to 6 months and an improvement in 1-year survival from 20 % to 
29 %.37 Later, meta-analyses have demonstrated that platinum-based combination 
chemotherapy is superior to single-agent therapy.50,51 
Several new, “third-generation”, cytotoxic drugs were developed in the 1990s. 
Most important were vinorelbine, gemcitabine, docetaxel and paclitaxel. Several 
studies have demonstrated that these agents in combination with cisplatin are more 
effective than single-agent cisplatin52,53 and older cisplatin-based combinations,54-56 
but no particular combination has proven to be superior to the others.57,58 Typically, 
response rates of 30-40 %, median OS of 7-12 months and a 1-year survival of 30-40 
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% have been achieved in clinical studies of combinations of third-generation and 
platinum compounds. 
With the introduction of third-generations drugs, there has been some interest 
in non-platinum doublet chemotherapy. Several combinations have showed similar 
efficacy and signs of less toxicity compared with platinum-combinations,59-62 and non-
platinum combinations are considered to be an alternative to platinum-doublets.36 
Higher response rates have been observed for three-drug combinations when 
compared with doublets, but these regimens cause more toxicity and have failed to 
prolong survival.51 
Carboplatin 
Carboplatin, a platinum-analogue, entered clinical trials in the early 1980s. The 
compound is easier to administer (since the long pre- and posthydration needed for 
cisplatin is not required) and causes less neurotoxicity, nephrotoxicity, nausea and 
vomiting. However, carboplatin induce more myelosupression (especially 
thrombocytopenia) than cisplatin.63,64 
There is an ongoing debate whether carboplatin is as effective as cisplatin. No 
single study has been able to definitely answer this question, but in two meta-
analyses, cisplatin was found to give higher response-rates and longer survival when 
combined with a third-generation drug.63,64 This difference was not detected in a third 
meta-analaysis.65 In palliative therapy, especially in patients with poor performance 
status, carboplatin is often preferred due to easier administration and less subjective 
toxicity – though the meta-analyses did not include patient reported outcomes. 
In the first clinical trials on carboplatin, the administered dose was around 400 
mg/m2. It was soon observed that patients with reduced renal function had more 
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thrombocytopenia than others.66,67 Hence, it has become more common to calculate 
the dose of carboplatin according to the renal clearance of the drug. 
Two formulas have been developed to estimate the dose for the individual 
patient; Calvert’s and Chatelut’s formula. Calvert’s formula was derived from 
estimating the correlation between the plasma-concentration of carboplatin and 
glomerular filtration rate (GFR) in patients who received the drug. The formula was 
then validated in another population and refined to: 
 
Dose (mg) = target area under the free carboplatin plasma concentration versus time curve (AUC) x 
(GFR + 25).68 
 
The best method for estimating GFR is to measure renal clearance of an radioactive 
isotope such as CrEDTA,69 but since this method is time-consuming and not 
available in all hospitals, it is common to estimate GFR by calculating creatinine-
clearance using Cockcroft-Gault’s formula:70 
Creatinine-clearance = 
€ 
(140 − age y[ ])x(bodyweight kg[ ])
72xserum − creatinine mg /dl[ ]
 x .85 if a woman 
The most common dose in advanced NSCLC is Calvert AUC=6.71,72 
Chatelut’s formula was derived from analyses of 34 patients receiving 
carboplatin. The formula was then validated in 36 other patients and the following 
formula was found to best predict carboplatin-clearance (CL): 
 
Dose (mg) = carboplatin-clearance (CL) / AUC73 
 
where CL was defined for men as: 
CL (mg/dl) =
€ 
0.134xbodyweight kg[ ] + 0.686x 218xbodyweight kg[ ]x(1− 0.00457xage y)[ ]serum − creatinine mg /dl[ ]x88.4
 
and for women as: 
  21 (127) 
CL (mg/dl) =
€ 
0.134xbodyweight kg[ ] + 218xbodyweight kg[ ]x(1− 0.00457xage y)[ ]serum − creatinine mg /dl[ ]x88.4
 
A common dose in advanced NSCLC is Chatelut AUC=4.38,39 
 The Calvert’s formula is considered the best method for calculating the 
carboplatin-dose provided the GFR is measured.68,73 Studies have demonstrated that 
Calvert’s formula substituting the measured GFR with a calculated creatinine-
clearance (Cockcroft-Gault’s formula) is better for predicting the correct dose of 
carboplatin than Chatelut’s formula,74,75 and most studies on NSCLC use this 
method. 
Duration of chemotherapy 
The optimal duration of therapy has been the subject to several studies.76 The 
survival benefit of chemotherapy is limited, and the treatment often causes side-
effects that may influence the patient’s well-being. Several studies have showed 
higher response-rates and longer progression-free survival, but not prolonged 
survival, from more than 3-4 cycles of chemotherapy.38,77,78 
Worth noticing, however, is that a recent study demonstrated that 
maintenance pemetrexed therapy prolonged survival when compared to BSC alone 
in patients who did not progress during four cycles of platinum-based first-line 
chemotherapy.79  
Treatment of patients with poor performance status and elderly 
Among patients with advanced NSCLC, performance status (PS) (Table 5) is the 
most important prognostic baseline characteristic.24,80 There is a general agreement 
that patients with PS 3 - 4 do not have a survival benefit from chemotherapy and 
patients with so poor general condition would have a high risk of experiencing severe 
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toxicity. It is debated what the optimal therapy for PS 2 patients is, while all PS 0-1 
patients receive chemotherapy unless there are specific, individual contraindications. 
Early it was recognized that PS 2 patients have significantly shorter survival 
than better functioning patients24 and subgroup analyses suggest that they 
experience more toxicity and lower RR.57,81-83 In a study comparing four of the most 
commonly used regimens in advanced NSCLC, accrual of PS 2 patients was stopped 
due to short survival and a high incidence of adverse events including five deaths.57 
On a closer look, however, only two of the deaths were considered related to the 
study treatment – which was similar to the proportion of treatment related deaths 
among PS 0-1 patients.84 On the other hand, in the meta-analysis of chemotherapy 
compared with BSC alone, the PS 2 had a statistically similar survival benefit as the 
PS 0-1 patients29 and a recent publication shows that PS 2-patients had more 
improvement of HRQoL from chemotherapy than patients with PS 0-1.85 
Unfortunately, PS 2 patients have been excluded from many of the recent large, 
randomized studies11,40,79 - due to concerns about tolerability and lack of benefit from 
the treatment. 
Several studies have shown that single-agent therapy with modern agents is 
superior to BSC alone, and some argue that PS 2 patients should be offered 
monotherapy since it is less toxic than combination therapy,86-88 Only one study has 
compared monotherapy with platinum-doublet chemotherapy in PS 2 patients. 
Combination therapy led to significantly higher RR (36 % vs 12 %), longer PFS (4 vs. 
2.8 months; p=.32) and OS (6.9 vs. 5.2 months; p=.38). Unfortunately, the power of 
the study was low since accrual was stopped before the target number of patients 
was reached. Subgroup analyses from larger randomized trials, suggest that doublet 
chemotherapy increases response rates and prolongs survival when compared to 
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monotherapy also for PS 2 patients83,89. Considering that a large proportion of 
patients have poor performance status, there is a need to enroll these patients onto 
clinical studies to gain further knowledge about how they should be treated. 
There is also little evidence to define the optimal therapy for elderly. Despite 
the fact that the median age at diagnosis is approximately 70 years, elderly are 
consistently under-represented in clinical trials.90-92 The definition of “elderly” also 
varies from 65-75 years. 
The benefit of chemotherapy among elderly (> 70 years) was demonstrated in 
a study comparing vinorelbine monotherapy with BSC alone;86 patients who received 
chemotherapy had significantly longer survival and reported better HRQoL. In the 
meta-analysis of chemotherapy compared to BSC alone, the elderly had the same 
benefit from the therapy as younger patients.37 
One trial suggested a survival benefit of gemcitabine plus vinorelbine over 
vinorelbine alone,93 while others have failed to confirm the superiority of non-platinum 
doublets over single-agent therapy.94,95 No studies have compared monotherapy with 
a platinum-doublet, though subset analyses have indicated that elderly benefit from 
and tolerate standard chemotherapy as well as younger patients.96,97 However, 
looking at the eligibility criteria in these studies, one can question whether the elderly 
patients analyzed are fully representative for the patients seen in the everyday clinic; 
patients with performance status 2 or severe comorbidity were excluded. 
  
General recommendations for the treatment of 
small-cell lung cancer 
Untreated, small-cell lung cancer (SCLC) is an aggressive disease with a median 
survival of 2-4 months.22 One reason is that SCLC spread rapidly and in most cases 
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has to be considered a systemic disease even in lower TNM-stages. This is probably 
the reason why randomized studies have failed to demonstrate a survival benefit of 
surgery in SCLC.98,99 
Still, there are data suggesting that surgery may improve survival in very early 
disease100,101 and in carefully selected patients;101,102 possibly due to better methods 
for staging than when the randomized trials were conducted. Adjuvant chemo- and 
radiotherapy are often administered after surgery.101,102 In Norway approximately five 
patients undergo surgery for SCLC annually.103 
Chemotherapy is the primary therapy for patients with locoregional or 
metastatic disease. In 1969, cyclophosphamide was the first drug to demonstrate a 
survival benefit over best supportive care in SCLC.22 Later, other agents such as 
doxorubicin,104 vincristine,105 etoposide106 and cisplatin107 demonstrated activity in 
SCLC. Further studies established etoposide plus cisplatin (EP) as the standard 
combination; a meta-analysis demonstrated that cisplatin-containing regimens were 
superior to non-platinum combinations108 and a review concluded that etoposide-
containing combinations were superior to other regimens.109 Later, a phase III 
confirmed that EP was superior to CAV (cyclophosphamide, adriamycin and 
vincristine), though the benefit was mainly observed in patients with LD.110 
In recent years, several studies have investigated the role of irinotecan in 
SCLC111-114 after a Japanese study demonstrated that irinotecan plus cisplatin was 
superior to EP in ED SCLC (9.4 vs. 12.8 months, p=.002).115 Only one study was 
able to confirm that irinotecan was superior to etoposide,114 and cisplatin plus 
etoposide is still considered the standard regimen; though a review concluded that 
irinotecan provides a longer overall survival and higher response rates than 
etoposide.116 
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Since SCLC is very sensitive to chemotherapy, several methods for 
intensifying chemotherapy have been investigated; three drug combinations with and 
without granulocyte colony stimulating agents,117-119 maintenance chemotherapy120 
and high-dose chemotherapy with or without autologous stem-cell transplantation.121-
124 These regimens have resulted in higher response rates, longer progression free 
survival, but not prolonged overall survival. They are also more toxic. 
Carboplatin is more convenient to administer and except for myelosupression, 
the compound offer less toxicity than cisplatin. For that reason, it may be more 
suitable to elderly and patients with severe comorbidity. The conclusion of a review 
was that carboplatin provides the same efficacy as cisplatin in SCLC.125 However, 
the studies reviewed had small sample sizes; only one phase III study has compared 
carboplatin with cisplatin in addition to etoposide in SCLC.126 In this study, similar 
efficacy was observed in both arms, but the study only enrolled a total of 143 
patients. Thus, cisplatin is considered to be the standard platinum compound – at 
least in patients with LD SCLC110,127 and in patients with ED SCLC who have a good 
performance status.111,112,128  
The first studies on the combination of chemotherapy and thoracic 
radiotherapy (TRT) were conducted in the 1970s.129,130 The role of TRT was 
controversial until a meta-analysis of 16 trials demonstrated a 14 % reduction in 
mortality corresponding to an increase in 3-year survival from 8.9 to 14.3 % 
(p=.001).131 One reason was that TRT in combination with alkylating agents result in 
severe toxicity and TRT had to be administered before, in-between or after the 
chemotherapy. In contrast, TRT can be administered concurrent with EP – which is 
more effective than sequential therapy; a meta-analysis suggest that minimizing the 
time from start of chemotherapy until the end of TRT improves survival.132 The 
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methods for staging and techniques for radiotherapy at that time may also be 
reasons for why the survival benefit of combined modality therapy was difficult to 
detect. 
The optimal radiotherapy-schedule remains to be defined. In the first trials, 32-
50 Gy were administered in 8-25 fractions, later 45 Gy/25133 fractions and 40 
Gy/15134 fractions were commonly used schedules. The longest survival has been 
observed in a trial comparing 1.5 Gy/2 fractions a day in 15 days with 45Gy/25 
fractions.127 The patients who received twice-daily radiotherapy had a significantly 
longer survival (23 vs. 19 months, p=.04) and a higher proportion survived 2 years 
(47 % vs. 41 %) and 5 years  (26 % vs. 16 %). A question remains, however; if time 
from start of chemotherapy until end of TRT influences survival, e.g. 40 Gy /15 
fractions may provide the same efficacy. 
At diagnosis, approximately 10 % of SCLC patients have brain metastases 
and up to 50 % develop during the course of the disease. Brain metastases often 
cause severe morbidity and are a common cause of death, especially in patients who 
have no systemic progression. Since the 1970s, the brain has been considered as a 
sanctuary where micrometastases survive due to poor penetration of cytotoxic drugs 
through the blood-brain barrier.135 Hence, prophylactic cranial irradiation (PCI) was 
investigated as a method for preventing development of brain metastases. The early 
studies demonstrated a lower frequency of brain metastases, but not prolonged 
survival.136 A possible explanation was that PCI only prolonged survival in patients 
who had a complete or near complete response to chemotherapy, since patients with 
systemic progression would die of failure of other organs than the brain.137 PCI was 
established after a meta-analysis demonstrated that patients with LD SCLC in 
complete remission after primary chemotherapy (or chemoradiotherapy) had a 16 % 
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risk reduction of death corresponding to an improvement in 3-year survival - from 15 
% to 21 % - as well as a reduction in the risk for developing brain metastases of 54 
%.138 
A recent study, have demonstrated that also patients with ED SCLC who 
respond to primary chemotherapy have a lower risk for developing brain metastases 
(15 % vs. 40 %) and prolonged survival (6.7 vs. 5.4 months) if they receive PCI.139 
In LD SCLC, approximately 80 % of patients respond to primary therapy and 
median survival is 15-22 months;110,127,134 5-year survival 9-26 %.110 Patients with 
ED-SCLC typically respond in 40-50 % of cases and have a median survival of 8-10 
months;110,111 2-year survival is 4-8 %.110,111 A large proportion (37 – 60%) of patients 
are offered second-line110,111 – and some even third-line140 – chemotherapy at 
relapse. Palliative radiotherapy is offered as in NSCLC. 
 
Second-line chemotherapy in recurrent SCLC 
Despite high response-rates to primary therapy, few patients with SCLC are cured. In 
ED SCLC, median progression free survival is 4-6 months,111,112 in LD SCLC 12-15 
months.134 
At relapse, most patients are considered for second-line therapy. Several 
regimens have yielded response rates of 10-25 % and a median survival of 25-39 
weeks in recurrent disease.141-144 Response and response-duration after first-line 
chemotherapy is the strongest predictive factor for response to second-line 
therapy.141,145 Patients with a response-duration of > 3 months are therefore defined 
as “sensitive” and those with shorter response duration as “refractory”. 
Few have investigated the absolute benefit of salvage therapy. A study 
investigating the duration of chemotherapy for SCLC suggested that chemotherapy 
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at relapse prolonged survival.30 In this study, patients were first randomized to 
receive either four or eight cycles of primary chemotherapy (cyclophosphamide, 
vincristine and etoposide). On disease progression, the patients were then 
randomized to receive either second-line chemotherapy (up to nine cycles of 
methotrexate plus doxorubicin) or symptomatic treatment alone. The patients who 
received four cycles only had an inferior survival (30 weeks) compared with the other 
groups (38-42 weeks, no significant difference between the groups). 
The only randomized study to compare second-line chemotherapy with BSC 
alone was published as late as in 2006. Onto this trial, 141 patients considered 
ineligible for intravenous chemotherapy were enrolled. Patients who received oral 
topotecan had longer survival (26 vs. 14 weeks; p=.01) and slower decline of 
HRQoL.146 It is worth noting that the patients enrolled were considered ineligible for 
intravenous chemotherapy and 53 % were “refractory”. The “sensitive” patients 
enrolled either refused intravenous chemotherapy due to concerns about toxicity or 
were found unsuitable for such therapy due to severe comorbidity. One would expect 
that the survival benefit is even larger for fit, “sensitive” patients, but this has in 
principle not been thoroughly investigated. 
 
Pemetrexed 
Molecular structure, mechanism of action and properties 
Pemetrexed, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl]benzoyl]-L-glutamic acid (LY231514) (Figure 6), is a synthethic antifolate that 
inhibits enzymes involved in growth and replication of tumor cells; more specifically 
three enzymes involved in purine and pyrimidine synthesis - thymidylate synthase 
(TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide 
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formyltransferase (GARFT) (Figure 7).147 Purines and pyrimidines are the building 
blocks of DNA and RNA. The drug is a substrate for the enzyme folylpolyglutamate 
synthetase (FPGS), which leads to polyglutamation of pemetrexed – converting the 
drug to a form that is retained intracellularly, producing a prolonged drug effect.148 
The multitargeted inhibition and the prolonged action may explain why pemetrexed 
shows a broader and more potent antitumor activity than other antifolates such as 
fluorouracil, methotrexate and raltitrexed.149,150 
 
Figure 6 Molecular structure of pemetrexed (LY 231514) 
 
 
 
 
Figure 7 Mechanisms of action of pemetrexed 
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In preclinical models, pemetrexed has demonstrated activity against several 
tumor types: Colon, renal and hepatic cancer – as well as NSCLC and SCLC.147 
Pemetrexed is rapidly eliminated (half-life of 3.5 hours), mainly via the kidneys 
(70-90 % of the drug is found in the urine within 24 hours).151 In a phase I trial, 
increased drug exposure was observed in patients with impaired renal function, and 
a patient with GFR of 19 ml/min died of drug related toxicity.152 Hence, it is 
recommended that patients have a creatinine-clearance of > 45 ml/min and do not 
use concurrent high-dose acetylic-salisylic acid (ASA) or non-steroidal anti-
inflammatory drugs (NSAIDs). 
Toxicity profile and the role of supplementation with vitamin B12 
and folic acid 
After the initial phase I/II trials, a schedule of a 10-minute infusion every 3 weeks of a 
dose of 500 mg/m2 was selected for further clinical trials.153 The dose-limiting toxicity 
was grade 3-4 neutropenia and thrombocytopenia.153 Other common toxicities were 
diarrhea, oral mucositis and rash. Prophylactic use of corticosteroids reduces the 
frequency of rash.153 
In the first phase III trial of pemetrexed,154 onto which patients with malignant 
mesothelioma were enrolled, there was initially a high incidence of treatment-related 
deaths. A multivariate analysis in another study showed that elevated levels of 
homocysteine and methylmalonic acid were associated with febrile neutropenia.155 
Subsequently, all new patients in the mesothelioma-trial were supplemented with 
folic acid and vitamin B12. This led to a reduction in the frequency and severity of 
hematologic and non-hematologic toxicities. This again led to longer survival in 
supplemented patients – probably since they were able to receive more 
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chemotherapy.154 The most common side-effects in the supplemented patients were 
nausea, fatigue, vomiting, diarrhea, dehydration and stomatitis.154,156  
Later, new phase I trials have demonstrated that a pemetrexed-dose of 1000 
mg/m2 is well tolerated in supplemented patients.157,158 Consequently, it is 
recommended that all patients who receive pemetrexed are supplemented with 
vitamin B12 and folic acid. 
Clinical trials 
In early clinical trials, single-agent activity was observed in patients with malignant 
mesothelioma,71 NSCLC,159 colorectal,160 pancreatic, bladder,161,162 head and 
neck,163 cervical,162 gastric164 and breast carcinomas.163  
In the first study to show a significant survival benefit of chemotherapy in 
malignant pleural mesothelioma, patients who received pemetrexed plus cisplatin 
had a longer survival than patients receiving cisplatin alone (12.1 vs. 9.3 months, 
p=.020).154 
Pemetrexed in lung cancer 
Results from several clinical studies of pemetrexed in the treatment of lung cancer 
were available when our studies were designed. 
A phase II study showed promising activity of pemetrexed in combination with 
carboplatin and cisplatin as first-line therapy of ED SCLC.165 Response rates, median 
survival time and 1-year survival was 35 %, 7.6 months, and 33 % for the cisplatin-
combination; 40 %, 10.4 months and 39 % for the carboplatin combination. This is 
similar to what has been observed in studies of EP in ED SCLC.110,111 
A phase III study of second-line therapy in NSCLC, showed that pemetrexed 
monotherapy was as effective and less toxic than the standard therapy at that time – 
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docetaxel monotherapy.156 Two phase II studies demonstrated single agent activity in 
chemonaive NSCLC patients.159,166 
 
Table 6  Phase II studies of pemetrexed monotherapy as first-line therapy of NSCLC 
 Chemotherapy n Response rates 
Overall 
survival 
1-year 
survival 
Rusthoven159 Pemetrexed 5-600 mg/2 33 23 % 9.3 months 25 % 
Clarke166 Pemetrexed 600 mg/m2 59 16 % 7.2 months 32 % 
 
 
Four phase II studies demonstrated that patients receiving pemetrexed-platinum 
combinations as first-line therapy had similar response rates and overall survival72,167-
169 as observed for standard regimens (Table 7).57,58 In two of these trials, patients 
were supplemented with vitamin B12 and folic acid without signs of reduced 
efficacy.72,168 The toxicity profile of the pemetrexed combinations appeared to be 
favorable, especially in patients who were supplemented with vitamin B12 and folic 
acid (Table 7). 
 
Table 7 Efficacy and hematologic toxicity in phase II studies of pemetrexed-platinum 
combinations as first-line therapy of NSCLC compared with commonly used regimens 
at that time. In the studies by Zinner and Scagliotti, the patients were supplemented 
with vitamin B12 and folic acid. 
 
 Chemotherapy n Response rates 
Overall 
survival 
1-year 
survival 
Manegold169 Pemetrexed 500 mg/
2  + 
Cisplatin 75 mg/m2 36 39 % 10.9 months 50 % 
Shepherd167 Pemetrexed 500 mg/m
2 + 
Cisplatin 75 mg/m2 31 45 % 8.9 months 49 % 
Zinner72 Pemetrexed 500 mg/m
2 + 
Carboplatin AUC = 6 50 24 % 13.5 months 56 % 
Scagliotti168 
Pemetrexed 500 mg/m2 + 
Carboplatin AUC = 6 or 
Oxaliplatin 120 mg/m2 
39 
 
41 
32 % 
 
27 % 
10.5 months 
 
10.5 months 
44 % 
 
50 % 
Schiller57 Paclitaxel 135 mg/m
2 + 
Cisplatin 75 mg/m2 288 21 % 7.8 months 31 % 
 Gemcitabine 1000 mg/m
2 
+ Cisplatin 75 mg/m2 288 22 % 8.1 months 36 % 
 Docetaxel 75 mg/m
2 + 
Cisplatin 75 mg/m2 389 17 % 7.4 months 31 % 
 Paclitaxel 225 mg/m
2 + 
Carboplatin AUC=6 290 17 % 8.1 months 34 % 
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Grade 3-4 toxicity Anemi Neutropenia Thrombocytopenia 
Manegold169 Pemetrexed 500 mg/
2  + 
Cisplatin 75 mg/m2 14 % 59 % 17 % 
Shepherd167 Pemetrexed 500 mg/m
2 + 
Cisplatin 75 mg/m2 20 % 37 % 3 % 
Zinner72 Pemetrexed 500 mg/m
2 + 
Carboplatin AUC = 6 2 % 26 % 2 % 
Scagliotti168 
Pemetrexed 500 mg/m2 + 
Carboplatin AUC = 6 or 
Oxaliplatin 120 mg/m2 
2 % 
 
8 % 
7 % 
 
26 % 
2 % 
 
18 % 
Schiller57 Paclitaxel 135 mg/m
2 + 
Cisplatin 75 mg/m2 13 % 75 % 6 % 
 
Gemcitabine 1000 mg/m2 
+ Cisplatin 75 mg/m2 28 % 63 % 50 % 
 
Docetaxel 75 mg/m2 + 
Cisplatin 75 mg/m2 15 % 69 % 3 % 
 
Paclitaxel 225 mg/m2 + 
Carboplatin AUC=6 10 % 63 % 10 % 
 
 
Measuring health related quality of life in lung 
cancer trials 
The definition of health related quality of life 
Quality of life (QoL) is a commonly used term, though it is not easily defined. The 
interpretation of the term varies depending on the context – and it can mean different 
things to different people. “Quality of life” can be used to describe the level of general 
health, satisfaction, ability to cope, happiness, being in control and the degree of 
independence.170,171 
 In medical research, one is usually concerned with evaluating the aspects of 
quality of life that are related to health - and the term can be linked to the World 
Health Organization’s definition of health: “A state of complete physical, mental and 
social well-being, and not merely the absence of disease and infirmity”.172 To 
distinguish between QoL in general and the aspects of interest in medical research, 
the term Health related quality of life (HRQoL) - defined as the dimensions of QoL 
that are most influenced by health and health-care interventions - has been 
introduced.173 
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The role of measuring HRQoL 
A large proportion of cancer research focuses on improving survival. However, side-
effects from therapy are common and the treatment can severely reduce a patient’s 
HRQoL. On the other hand, a new therapy can be beneficial even if it does not 
improve efficacy (in terms of objectively measurable parameters such as response 
rates, progression free survival and overall survival) if it provides better HRQoL. 
Hence, it is of great importance to measure the impact on HRQoL when introducing 
new therapies – especially when the survival benefit is as limited as in advanced lung 
cancer. Studies have demonstrated that health care professionals tend to 
overestimate the benefit and underestimate the side-effects from therapy while the 
patient’s reports may be more valid.174-176 
Measurement of HRQoL in lung cancer trials 
Already in the first trial of palliative chemotherapy in lung cancer, subjective 
improvement was defined as one of the endpoints.28 The authors of the meta-
analysis of studies comparing chemotherapy in advanced NSCLC with best 
supportive care alone conclude that chemotherapy most likely improve HRQoL, but 
the scientific evidence is limited, since so many different methods for assessing 
HRQoL were used in the studies reviewed.37 Later studies using more generally 
accepted instruments for measuring HRQoL confirmed this assumption.86,177,178 
Other studies have demonstrated that second-line chemotherapy179 and erlotinib180 
improves HRQoL in recurrent NSCLC. 
Instruments for measuring HRQoL 
There is an international agreement that HRQoL should be measured using a 
multidimensional, validated instrument. The most commonly used in lung cancer 
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trials are the Functional Assessment of Cancer Therapy – Lung (FACT-L),181 the 
Lung Cancer Symptom Scale (LCSS)182,183 and the European Organization for 
Research and Treatment of Cancer Core Questionnaire (EORTC QLQ C30) plus the 
Lung Cancer supplement (LC 13) (Appendix A).184,185 There are certain differences in 
what they measure, but in general none have proven to be superior to the others. 
The C30 and LC 13 have been validated, have been translated into Norwegian and 
have been used in several trials in lung cancer - both in first-38,39,58,86,177 and second-
line treatment179,180 of NSCLC; two of these were conducted by the Norwegian Lung 
Cancer Study Group.38,39 
The EORTC QLQ C 30 plus LC 13 
The EORTC QLQ C 30 (published in 1993)184 consists of 30 questions and measures 
13 fundamental aspects of HRQoL and symptoms commonly reported by cancer 
patients (Table 8). Nine of the scales are multi-item scales: Five functional scales 
(physical, role, emotional, cognitive and social function); three symptom scales 
(fatigue, pain and nausea/vomiting); and one scale for global health status and 
quality of life. Six single item scales assess common symptoms (dyspnea, appetite 
loss, sleep disturbance, constipation and diarrhea) and the perceived financial impact 
of having a malignant disease. 
The Lung Cancer specific module, LC 13, consists of 13 questions and 
measures symptoms commonly associated with lung cancer and its treatment.185 
Dyspnea is measured with a multi-item scale, the other are single-item scales.  
When answering the QLQs, the patients give a score 0-7 for the two questions 
about global QoL, for the other questions they give a score 0-4. The questionnaires 
are shown in Appendix A. 
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Table 8  Content of the EORTC QLQ C30 plus LC13 
QLQ Type of scale Scale No. of items Question no. 
     C30 Global Health/QoL Global QoL 2 29, 30 
     
 Functional scales Physical function 5 1-5 
  Role function 2 6,7 
  Emotional function 4 21-24 
  Cognitive function 2 20,25 
  Social function 2 26,27 
     
 Symptom scales Fatigue 3 10,12,18 
  Nausea and vomiting 2 14,15 
  Pain 2 9,19 
  Dyspnea 1 8 
  Insomnia 1 11 
  Appetite loss 1 13 
  Constipation 1 16 
  Diarrhea 1 17 
  Financial difficulties 1 28 
     
LC13 Symptom scales Dyspnea 3 3-5 
  Coughing 1 1 
  Hemoptysis 1 2 
  Sore mouth 1 6 
  Dysphagia 1 7 
  Peripheral neuropathy 1 8 
  Alopecia 1 9 
  Pain in chest 1 10 
  Pain in arm or shoulder 1 11 
  Pain in other parts 1 12 
 
 
Analyzing HRQoL reported on the EORTC QLQ C30 and LC 13 
Before conducting the analyses, scores for each scale have to be calculated 
according to the scoring manual developed by the EORTC.186 In general, the raw 
scores are transformed linearly to a scale from 0-100 – taking into consideration all 
items for each scale. A high score on functional scales means a good function/quality 
of life, while a high score on symptom scales means severe symptoms and hence a 
poor quality of life. If more than half of the items are not completed, the scale score is 
defined as missing. 
 There are several methods for analyzing the HRQoL-scores. The most 
common analysis is to compare mean scores for each scale at each time-
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point.38,39,86,177 Others have reported the change from baseline scores until defined 
time-points for re-assessment of HRQoL;177-179 calculated the area under the curve 
(AUC) for each scale during the period defined as of interest;39 compared proportions 
of patients who had improvement, stable or worse HRQoL during a period;180 or 
compared the time to deterioration of HRQoL.180 
 To ensure valid results, one should define which scales that are of primary 
interest – and what analyses that will be performed. This will limit the risk for finding 
significant differences by chance. In addition, the period of interest should be defined. 
In clinical studies of treatment of cancer patients, there may be several factors 
interfering with HRQoL soon after the study treatment period - such as progressive 
disease, salvage therapy and other medical symptom relief. 
Compliance 
A common challenge is to have a high compliance for the quality of life 
questionnaires (QLQs). In study populations like patients with advanced NSCLC, the 
participants are old, frail and in many cases, their physical condition deteriorates 
rapidly. 
If data are missing by random, the results are less likely to be biased. In a 
large, randomized trial this may be the case if compliance is similar within all 
treatment groups. However, there are data suggesting that the most ill are less likely 
to complete QLQs as scheduled. Hence, if there is a difference in the efficacy of the 
different study therapies, this may influence the completion rate in the respective 
arms. 
Missing data may also reduce power of the analyses due to reduced sample 
size. This can to some extent be overcome by increasing the number of patients on a 
study, but will not necessarily reduce potential biases. 
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When it comes to measurement of HRQoL by QLQs, there are two types of 
missing data – missing QLQs (not handed to the patient, not completed by the 
patient or lost, completed QLQs) and missing items (partially incompleted QLQs). 
There are two patterns of missing data – terminal (no further data available) or 
intermittent (one or more observations missing, but later QLQs completed). Terminal 
dropout may occur if a patient withdraws from the study, does not want to answer 
more questionnaires or dies. Intermittent missing forms may be related to intercurrent 
illness.187 
There are no established limit for the proportion of responders required for 
considering the analyses valid, though a compliance of more than 80 % has been 
suggested as adequate.188 
In the previous trials by NLCG, the baseline QLQ has been handed to the 
patient and completed before randomization, and the following QLQs have been 
mailed directly to the patients from the study office. Compliance has been high (> 80 
%), which may be due to the central distribution of the QLQs.187 
Imputation of missing values 
Intuitively, one would believe that only the reported values should be analyzed. This 
would also be the easiest way of conducting the analyses. However, the sample size 
would in many cases be significantly reduced since it is very difficult to ensure that all 
QLQs are completed according to the study plan. In addition, only analyzing reported 
values may cause a selection bias. 
 Imputation of missing values is a method for overcoming the problem with 
incomplete or missing questionnaires; at least when the overall compliance is fairly 
high and it is reasonable to assume that the data are missing at random. There are 
several methods for imputation and what method to apply will depend on the 
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circumstances that have lead to missing data. Most importantly, the methods needs 
to be predefined and the data should be analyzed using more than one method for 
imputation (performing a sensitivity test) to test the impact of the model for 
imputation.187 
 
Comorbidity in cancer patients 
Comorbidity as a prognostic factor in cancer patients 
Cancer is more frequent with increasing age; 74 % of new cases in Norway in 2007 
were diagnosed in patients ≥ 60 years, 48 % in patients ≥ 70 years (Figure 8).2 Due 
to the general ageing of the population, the number of cancer patients and the 
proportion of elderly cancer patients are expected to increase in the future. 
 
Figure  8 Age distribution of new cases of cancer in Norway in 2007 
 
 
 
Comorbidity - the presence of co-exisiting disorders or diseases – is more frequent in 
elderly patients,189,190 and for that reason, knowledge about how physicians are to 
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treat cancer patients with several or severe disorders is needed. There are reports 
indicating that these patients do not receive the same therapy as patients with a 
better general health,191-193 possibly due to concerns about whether they benefit from 
or tolerate standard treatment. However, there is little evidence for how patients with 
several co-existing diseases should be managed. Unfortunately, comorbidity is 
seldom systematically measured or reported – and elderly and patients with 
comorbidity are often underrepresented or excluded from clinical trials.90-92,194 Thus, 
many of the treatment recommendations are based on studies of patients with other 
features than a large proportion of the patients seen in the everyday clinic.194  
Patients need to have a reasonable good general health to tolerate many of 
the therapies for cancer. Surgery necessitates anesthesia - which can only be given 
to respiratory and circulatory stable patients. Radiotherapy often leads to impaired 
function of vital organs, and chemotherapy can only be administered to patients with 
adequate organ function; particularly hematopoietic, liver and kidney function. 
Several studies have shown that patients with severe comorbidity have inferior 
survival among patients with colon-, breast-, prostate-, lung- and head and neck 
cancer.195,196 However, one cannot necessarily apply the results from these trials to 
cancer patients in general since the methods for assessing comorbidity vary between 
studies. There may also be different impact of comorbidity on survival depending on 
what therapy the patients receive - and the prognosis of the underlying cancer. One 
study has demonstrated that the influence of comorbidity on survival was related to 
the expected survival time; the longer the patients lived with their cancer, the more 
likely it was that other disorders deteriorated to such an extent that it influenced the 
survival time.196 
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Denying elderly or patients with significant comorbidity therapy is hardly an 
option since these patients are frequent. To better be able to individualize therapy, 
there is a need for studies of the influence of comorbidity on survival, the efficacy and 
tolerability of therapy and the impact on HRQoL. 
Prognostic and predictive factors in advanced NSCLC 
The survival benefit of chemotherapy in advanced NSCLC is limited,37 the therapy is 
time consuming and patients frequently experience severe toxicity. Hence, a lot of 
research has focused on identifying the patients who benefit the most from the 
therapy – and subgroups that should be offered other treatment or best supportive 
care alone. 
 Performance status is the most important prognostic selection factor. PS 3-4 
patients are not routinely offered cytotoxic chemotherapy, how to treat PS 2 patients 
is debated while most PS 0-1 patients receive standard platinum-doublet 
chemotherapy. 
Subgroup analyses have revealed that stage of disease,11,19 male 
gender,11,197,198 a history of smoking,11,199 poor baseline HRQoL200-202 and weight-
loss202,203 are significant, negative prognostic factors. However, patients sharing one 
or more of these characteristics account for a very large proportion of patients and 
there is not sufficient evidence to deny these patients therapy.  
Co-existing disorders in lung cancer patients 
Lung cancer patients have a high frequency of co-existing disorders. Comorbidity 
increases with age, and more than half of the patients are > 70 years at diagnosis. In 
addition, most have been tobacco-smokers, a well-known cause of a wide range of 
diseases – especially disorders in the cardiovascular and respiratory systems such 
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as ischemic heart disease204,205 and chronic obstructive pulmonary disease 
(COPD).206,207 
A large proportion of lung cancer patients are diagnosed with advanced 
disease - which often causes poor performance status. The treatment is often 
demanding, and there are concerns about how well patients with severe comorbidity 
are able to tolerate chemotherapy.36,84 
Previous research on comorbidity in lung cancer 
Several studies have investigated the prognostic value of comorbidity in lung cancer 
patients. In stage I,208 stage III209 and mixed cohorts of lung cancer patients,196,200,210 
comorbidity has been identified as an independent prognostic factor for survival. This 
has not been observed in the studies that have analyzed patients with advanced 
disease separately.196,201,211  
 Few studies have looked at the association between comorbidity and 
tolerability of the therapy and the results are not consistent.210-212 No studies have 
investigated the relation to HRQoL in lung cancer patients. 
 Nevertheless, patients with severe comorbidity are excluded from or 
underrepresented in clinical trials,194 and studies have shown that patients with 
severe comorbidity are less likely to receive standard therapy in the clinic.191-193 
 
Measuring comorbidity 
Several instruments have been developed for measuring comorbidity. The most 
commonly used are the Charlson Comorbidity Index (CCI), the Cumulative Illness 
Rating Scale for Geriatrics (CIRS-G), the Index of Coexisting Diseases (ICED) and 
the Kaplain-Feinstein index. Recently, the Simplified Comorbidity Score (SCS) was 
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developed for assessing comorbidity in lung cancer patients (Table 9). All of these 
indices have been validated, and have been used in studies of cancer patients. 
Except for the CIRS-G, the indices rate the presence of a list of conditions that 
have been identified as significant prognostic factors in different cohorts. In contrast, 
the CIRS-G rates the presence and severity of all disorders on 14 predefined 
scales/organ systems. 
 
Table 9  Construction of instruments for measuring comorbidity. 
Scale Items and rating How constructed 
The Charlson 
Comorbidity Index 
19 disorders weighted 1 to 6 
Total score: 0 – 30 
1-year mortality in patients admitted to 
internal medicine department 
The Charlson 
Comorbidity Index + 
age 
Original Charlson + 1 point added 
for each decade ≥ 50 years of age 
Total score: 0 - 35 
Same as Carlson + validation study of 
breast cancer patients with 10 – year 
mortality as endpoint 
The Cumulative 
Illness Rating Scale 
(CIRS) 
Disorders in 13 organ systems 
rated 0 – 4 
Total score: 0 – 54 
Comprehensive listing of diseases 
weighted by clinician’s estimate 
The Cumulative 
Illness Rating Scale 
for Geriatrics 
(CIRS-G) 
Disorders in 13 organ systems 
rated 0 – 4 
Total score: 0 – 54 
Comprehensive listing of diseases 
weighted by manual – or clinician’s 
estimate if not listed in manual 
The Index of 
Coexisting Disease 
(ICED) 
Disease severity subindex: 14 
diseases rated 0 – 4 
Functional severity index: 
12 conditions rated 0 – 2 
Total score. 0 - 3 
Anticipated outcome 2 years after 
hospitalization in breast cancer 
patients 
The Kaplan-Feinstein 
Index scale 
12 conditions (10 diseases plus 
locomotive function and alcoholism) 
rated 0 – 3 
Total score: 0 - 3 
Study of disorders that may influcence 
survival in diabetics 
The Simplified 
Comorbidity Score 
(SCS) 
7 disorders weighted 1 to 7 
Total score: 0 – 20 
Retrospective analyses of 
comorbidities as significant prognostic 
factors for survival in 735 patients with 
NSCLC 
 
 
The Charlson Comorbidity Index (CCI) 
By analyzing 559 patients admitted to a hospital department of internal medicine, 
Charlson and colleagues identified 19 conditions associated with increased mortality 
within one year.213 When assessing comorbidity using this instrument, the presence 
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of these conditions are registered and scored before a final score is calculated. The 
index was later validated in a cohort of breast cancer patient where it was found to 
predict mortality over a period of a few weeks to 10 years.213 In the validation study, 
adding one point for each decade of age ≥ 50 years was suggested (Table 10). 
The CCI is the most commonly used. It is easy to use, and in an adapted 
version, comorbidity can be scored from databases of diagnose-codes.214,215 This 
makes it suitable for large studies and studies involving many sites and investigators. 
 
Table 10 The Charlson index for scoring of comorbidity 
Comorbidity Present Points 
Myocardial infarct   1 
Congestive heart failure  1 
Peripheral vascular disease  1 
Cerebrovascular disease (except hemiplegia)  1 
Dementia  1 
Chronic pulmonary disease  1 
Connective tissue disease   1 
Ulcer disease  1 
Mild liver disease   1 
Diabetes (without complications)  1 
Diabetes with end organ damage   2 
Hemiplegia  2 
Moderate or severe renal disease  2 
2nd solid tumor (non metastatic)   2 
Leukemia  2 
Lymphoma, multiple myeloma . . .  2 
Moderate or severe liver disease   3 
2nd metastatic solid tumor  6 
AIDS  6 
Total points   
 
Optional extension 
Age Present Points 
50 – 59  1 
60 – 69  2 
70 – 79  3 
80 – 89  4 
90 – 99  5 
Total combined score (comorbidity + age)   
 
 
 
The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) 
The Cumulative Illness Rating Scale was designed in 1968 as an instrument for 
comprehensive recording of comorbidity.216 Later, a manual recommending specific 
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scores for common conditions among geriatric cancer patients was developed - the 
Cumulative Illness Rating Scale for Geriatrics.217 This index scores all conditions on 
14 predefined scales/organ systems from 0-4 - similar to toxicity grading using the 
common terminology criteria for adverse events (CTCAE)218. In general, “0” indicates 
no problem, “1” indicates a current mild problem or a past significant problem, “2” a 
moderate disability or morbidity that requires “first-line” therapy, “3” a severe/constant 
significant disability or an "uncontrollable" chronic problem and “4” an extremely 
severe/immediate treatment required/end organ failure/severe impairment in function. 
The CIRS-G manual recommends specific scores for common conditions. Total 
score (= the sum of the score for all scales), the numbers of scores 3 and 4 and 
severity index (= total scores/number of categories with a score > 0) are then 
calculated (Table 11). 
A major difference from the CCI, is that it includes assessment of non-lethal 
conditions; some of significance for cancer patients receiving chemotherapy such as 
hematopoietic, renal and liver dysfunction. 
The grading of each condition gives a more detailed picture of the patient’s 
health than the CCI. The CIRS-G is more sensitive, but the clinical relevance 
(content validity) of this is unclear – though in two trials on stage I and stage III 
NSCLC, CIRS-G but not CCI scores were prognostic factors for survival.208 The 
drawback is that it requires more training and the scoring takes longer time compared 
with the less comprehensive indices. Thus, it can only be used in sites that have 
trained personnel – unless all information about co-existing disorders is sent for a 
central scoring.  
After our study was initiated, an updated version of the CIRS-G has been 
developed.219-221  
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Table 11 Example of comorbidity assessment in a patient using the CIRS-G 
Score 0 1 2 3 4 
   Heart  X    
   Vascular   X   
   Hematopoietic X     
   Respiratory    X  
   Eyes, ears, nose, throat and larynx X     
   Upper gastrointestinal tract X     
   Lower gastrointestinal tract  X    
   Liver X     
   Renal X     
   Genitourinary  X    
   Musculoskeletal/integument X     
   Neurological X     
   Endocrine/metabolic and breast X     
   Psychiatric illness X     
 
   Total number categories endorsed 5 
   Total score 8 
   Severity Index (Total score / Total number of categories endorsed) 1.6  (8/5) 
   Number of categories at level 3 1 
   Number of categories at level 4 0 
 
	  	  	  RATING	  STRATEGY	   
	  	  	  0	  -­‐	  	  No	  Problem	   
	  	  	  1	  -­‐	  	  Current	  mild	  problem	  or	  past	  significant	  problem	   
	  	  	  2	  -­‐	  	  Moderate	  disability	  or	  morbidity/requires	  "first	  line"	  therapy	   
	  	  	  3	  -­‐	  	  Severe/constant	  significant	  disability/"uncontrollable"	  chronic	  problems	  
	  	  	  4	  -­‐	  	  Extremely	  severe/immediate	  treatment	  required/end	  organ	  failure/severe	  impairment	  in	  function	   
 
 
 
The Index of Coexistent Diseases (ICED) 
The ICED was developed in 1987 as a tool in a study of whether physicians provided 
less intensive therapy in elderly patients than for younger patients. The purpose was 
to determine whether the presence of coexisting disorders influenced cancer 
management. Interestingly, the conclusion was that physicians made treatment 
decisions based upon age and not presence of comorbidity.222 The ICED has mostly 
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been used in studies of the relation between comorbidity and intensity of cancer 
treatment.223,224 
The index consists of two subscales; physical and functional. On the physical 
subscale, conditions are rated 0 to 4 on 14 subscales according to a manual; the 
functional rates disorders from 0 – 2 on 12 domains. The scores are then 
transformed into an overall score of 0 – 3.222 
 
The Kaplan-Feinstein scale 
This index was developed in 1974 and consists of a list of conditions that the authors 
considered could influence long-term survival in patients with diabetes mellitus. The 
conditions are grouped into 12 categories and rated 0 – 3 within each group after well 
defined guidelines. The number and severity of diseases are then transformed into a 
final score from 0 – 3.225 The Kaplan-Feinstein index has been used in studies of 
breast, prostate and head & neck cancer. 
 
The Simplified Comorbidity Score 
The SCS was developed by identifying conditions associated with increased risk of 
death in a population of 735 patients with NSCLC and consists of a list of seven 
conditions.226 All conditions give a score according to relative risk of death from 1 to 7 
for a total score of 0 – 20. The SCS has been validated in another population of 
NSCLC patients. In this study, the SCS was found to be more informative than the 
CCI in predicting outcomes in 301 patients with different stages of NSCLC.200 
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Research questions for the thesis 
• Do patients with recurrent small-cell lung cancer respond to and tolerate high-
dose pemetrexed monotherapy? 
  
• Does pemetrexed plus carboplatin offer better health-related quality of life with the 
same efficacy and less toxicity as a standard regimen in first-line treatment of 
advanced non-small-cell lung cancer? 
 
• Do non-small-cell lung cancer patients with severe comorbidity have a shorter 
survival, more toxicity or more deterioration of health-related quality of life during 
first-line chemotherapy than other patients? 
 
 
Rationale for the studies 
Results from preclinical studies153,227 as well as preliminary results from a phase II 
study on pemetrexed-platinum combinations as first line therapy in small-cell lung 
cancer,165 suggested that SCLC patients respond to pemetrexed therapy. There were 
also several studies suggesting that pemetrexed may be an effective treatment of 
NSCLC, and previous studies have demonstrated that agents used in the treatment 
of NSCLC can be effective in the treatment of recurrent SCLC.143,144 In addition, 
pemetrexed appeared to be well tolerated. Second-line therapy is administered to a 
large proportion of patients with recurrent disease, though there were no standard 
regimens at that time. Several regimens have demonstrated similar efficacy141-144 in 
terms of response rates, time to progression and overall survival. Thus, historical 
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data were accepted for defining sample size and defining what level of response 
would warrant further research. 
 When our study was designed, two other studies administering standard dose 
of pemetrexed (500 mg/m2) in recurrent SCLC were already initiated.228,229 Recent 
phase I studies suggested that a higher dose was tolerable in patients who were 
supplemented with vitamin B12 and folic acid.157,158 In general, it is assumed that a 
higher dose is more effective than a lower dose when administering chemotherapy. 
This was the rationale for investigating the efficacy of high-dose pemetrexed 
monotherapy in recurrent SCLC. 
 Phase I,230 II71,72,159,166,167,169 and III156 studies had demonstrated activity of 
pemetrexed (monotherapy or combinations with a platinum-compound) in NSCLC -
with a favorable toxicity profile. The survival benefit of chemotherapy in advanced 
NSCLC is limited, and there are concerns about toxicity for a large proportion of the 
patients; due to poor performance status, old age and severe comorbidity. If 
pemetrexed is as effective and less toxic than standard regimens, the drug may 
provide a better HRQoL. In addition, if more patients were able to tolerate 
chemotherapy, there may also be a survival benefit. This was the rationale for 
conducting a phase III study comparing pemetrexed plus carboplatin with a standard 
regimen, gemcitabine plus carboplatin, as first-line chemotherapy in advanced 
NSCLC. 
 Performance status is considered to be the most significant prognostic 
baseline characteristic. Several studies have demonstrated that the presence of co-
existing disorders may be a significant, independent prognostic factor in NSCLC and 
may predict more toxicity from therapy – which again could influence the HRQoL 
during therapy. As a result of an ageing population, physicians need to gain 
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knowledge about how to take comorbidity into consideration when making treatment 
decisions. Thus, patients who were enrolled onto the study of advanced NSCLC 
were analyzed for the associations between the presence of comorbidity and 
outcomes of the chemotherapy. 
 
Patient selection for the thesis 
Study populations 
Two separate patient populations were investigated (Table 12). The patients were 
recruited at a majority of hospitals diagnosing and treating lung cancer patients in 
Norway by investigators that are members of the Norwegian Lung Cancer Study 
Group. 
 
Table 12  Cohorts investigated. 
Paper Population Diagnosis Location Enrolment period n 
1 1 Recurrent SCLC Norway May – October 2005 36 
2 & 3 2 Stage IIIB/IV NSCLC Norway May 2005 - July 2006 446 
 
 
 
Eligibility criteria for all patients 
• Signed, written informed consent 
• Have the ability to understand oral and written information about potential 
benefits, side-effects or disadvantages of participating in the trials 
• WHO performance status 0-2 
• Creatinine clearance > 45 ml/min 
• No other clinically active cancer was allowed 
• No pregnant or lactating women were allowed  
• All fertile patients had to use safe contraception 
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Rationale for the eligibility criteria 
• The concept of voluntary participation is essential for conducting medical 
research in humans. 
• In order to tolerate experimental chemotherapy, a good performance status is 
needed. Previous studies have demonstrated that patients with advanced lung 
cancer and performance status 3-4 do not benefit from chemotherapy. 
• Pemetrexed is eliminated through the kidneys, and phase I data suggested a 
higher risk of toxicity in patients with a reduced renal function.152 
• Other active cancer could possibly influence the analysis and may warrant other, 
concurrent therapy. 
• Cytotoxic compounds may be teratogenic, and would put embryos and breast-fed 
children at risk. 
Study population 1 
The patients were enrolled at 16 hospitals in Norway between May and October 2005 
onto a phase II study conducted by the Norwegian Lung Cancer Study Group (Fig 9). 
 
Eligibility criteria (in addition to the above mentioned): 
• Histologically or cytologically verified SCLC 
• One previous chemotherapy regimen for SCLC (re-induction with same regimen 
allowed) 
• No systemic or experimental cancer-treatment four weeks prior to the first cycle of 
pemetrexed 
• Age 18-75 years 
• No symptomatic brain metastases 
• ANC > 1.5 x 109/L, platelets > 100 x 109/L, bilirubin < 1.5 x ULN 
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• ALT and ALP < 3 x ULN (If liver-metastases were present: < 5 x ULN) 
• Measurable disease according to the RECIST-criteria v1.0231 
 
Rationale for the eligibility criteria 
• To avoid potentially confounding toxicity from other therapy. 
• There were no data concerning tolerability of high-dose pemetrexed in elderly 
patients. In a previous trial investigating second-line therapy of SCLC in 
Norway,232 very few patients > 75 years received second-line therapy. 
• There was little knowledge about the efficacy of pemetrexed in brain metastases; 
and there were concerns about whether they would live long enough to be 
evaluated for the primary endpoint. 
• The values of the lab-tests were considered necessary for tolerating pemetrexed 
therapy. 
• Measurable disease was necessary to assess response – the primary endpoint of 
the study 
 
Figure 9 Patient selection for study 1 
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Study population 2 & 3 
The patients were enrolled at 35 hospitals in Norway from May 2005 - July 2006 onto 
a phase III study conducted by the Norwegian Lung Cancer Study Group (Fig 10). 
 
Eligibility criteria for the phase III study (Study 2) 
• Histologically or cytologically verified NSCLC 
• Stage IIIB (not eligible for curative radiotherapy) or stage IV disease 
• Age > 18 years 
• No previous systemic cancer treatment for NSCLC 
• ANC >1.5x109/L, platelets >100x109/L, bilirubin <1.5xULN, ALT and ALP <3xULN 
 
Additional eligibility criteria for the exploratory study of comorbidity (study 3) 
• Had received at least one cycle of study treatment 
• Had completed the baseline QLQ 
• A copy of the patient’s hospital medical records for the last 3 months prior to 
randomization in the phase III study was possible to retrieve 
 
Rationale for the eligibility criteria 
• To test the pemetrexed-carboplatin in a population as similar to the patients seen 
in the everyday clinic, as few limitations for the eligibility as possible were defined. 
• To analyze the influence of comorbidity on the outcome of chemotherapy, 
patients had to have received at least one cycle of study treatment and had to 
have completed the baseline quality of life questionnaire. 
• To ensure consistent comorbidity assessment, a central scoring was preferred. 
Thus, a copy of hospital medical records had to be available. 
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Figure 10 Patient selection for study 2 & 3 
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Study designs 
The studies had three different designs: 
• An open, prospective, national multicentre phase II study of the efficacy of high-
dose pemetrexed monotherapy in recurrent SCLC 
• An open, prospective, national, multicentre, randomized phase III study 
comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-
line chemotherapy in advanced NSCLC 
• An exploratory analysis of the associations between comorbidity assessed using 
the CIRS-G and clinical outcomes in patients who received first-line 
chemotherapy in the phase III study. 
 
Table 13 List of studies 
Study Design Patient reported Physician reported Objectives 
1 Prospective phase II None 
Response-rates 
Toxicity 
Overall survival 
Response rates 
Overall survival 
Toxicity 
Time to progression 
2 Prospective phase III 
HRQoL on the 
EORTC QLQ 
C30/LC13 
Toxicity 
Overall survival 
HRQoL (Global QoL, fatigue, 
nausea/vomiting, dyspnea) 
Overall survival 
Toxicity 
3 Exploratory analyses 
HRQoL on the 
EORTC QLQ 
C30/LC13 
Comorbidity 
Toxicity 
Overall survival 
The associations between 
comorbidity and overall 
survival, toxicity and HRQoL 
 
 
Study treatment 
Study 1 
Up to four cycles of pemetrexed 900 mg/m2 every 3 weeks were administered. The 
patients were supplemented with folic acid and vitamin B12 from one week before 
the first and until 3 weeks after the last cycle of study treatment. 
 Prior to each course, ANC had to be ≥1.5×109/L, platelets ≥100×109/L, 
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creatinine-clearance ≥45mL/min and any grade 3–4 non-hematological toxicity had to 
be resolved. If not, treatment was delayed 1 week. The dose of the following course 
was reduced by 25% in case of nadir ANC <0.5 ×109/L, a neutropenic infection or  
any grade 3–4 toxicity following the preceding course. A 50% dose reduction was to 
be performed in case of nadir platelets < 50 ×109/L or grade 3–4 mucositis. Any dose 
reductions were maintained for all subsequent courses. If a patient qualified for a 
third dose reduction, or had a treatment-related delay of more than 42 days following 
the preceding course, the study treatment was discontinued. 
 
Study 2 & 3 
Patients were randomly assigned to receive pemetrexed 500 mg/m2 plus carboplatin 
AUC=5 on day 1 of every cycle - or gemcitabine 1,000 mg/m2 on days 1 and 8 plus 
carboplatin AUC=5 on day 1 of every cycle. The carboplatin dose was calculated 
using Calvert’s formula. Patients ≥ 75 years old had a 25% dose reduction. 
Chemotherapy cycles were repeated every 3 weeks for up to four cycles. All patients 
were supplemented with folic acid and vitamin B12 from one week before the first 
and until 3 weeks after the last cycle of study treatment. 
The doses of carboplatin and gemcitabine, and the dose-reductions in elderly 
≥ 75 years, were recommended due to experiences from a previous trial39 by the 
NLCG (unpublished data).  
Before the start of each cycle, ANC had to be ≥ 1.0 x 109/L, platelets ≥ 75 x 
109/L, creatinine-clearance ≥ 45 ml/min and grade 3-4 toxicities resolved. Otherwise 
treatment was delayed by one week. Doses for the following cycle were reduced by 
25 % if ANC was 1.0-1.49 x 109/L or platelets 75-99 x 109/L on day 22 after the 
preceding cycle, nadir ANC < 0.5 x 109/L, or the patient had experienced a grade 3-4 
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toxicity. Doses were reduced by 50 % in case of nadir platelets < 50 x 109/L or grade 
3-4 mucositis. Dose-reductions were maintained for subsequent cycles. The study-
therapy was discontinued if a patient qualified for a third dose-reduction or a cycle 
was delayed > 21 days. Omissions or reductions of the gemcitabine-dose on day 8 of 
a cycle were allowed. 
Evaluation and follow-up 
Study 1 
A baseline CT scan of the thorax and upper abdomen was performed within 1 week 
prior to the first cycle of chemotherapy. A clinical examination and a CT scan for 
response-evaluation were performed 3 weeks after the fourth course of 
chemotherapy and then every 8 weeks until progression (earlier if progression was 
suspected). Response was assessed according to the RECIST-criteria, but 
confirmation of response was not mandatory. 
All patients were observed for one year or until death. No central review of the 
CT-scans was performed. Hemoglobin, leukocytes, ANC and platelet count were 
measured on day 1, 8 and 15 of each treatment cycle. Toxicity was assessed at 
every visit and graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) v3.0.218 
 
Study 2 
A baseline CT scan of the thorax and upper abdomen was performed within 1 week 
prior to chemotherapy. HRQoL was assessed prior to randomization, before every 
cycle of chemotherapy, three weeks after the fourth and last cycle of chemotherapy 
and then every eight weeks until death or one year. 
Hemoglobin, leukocytes, ANC and platelet count were measured on day 1, 8 
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and 15 of each treatment cycle. A clinical examination was performed before every 
cycle of chemotherapy, three weeks after the last cycle and then every eight weeks 
until death or one year. Toxicity was assessed at every visit and graded according to 
the CTCAE v3.0. 
 
Study 3 
Hospital medical records for the last three months prior to randomization for patients 
entered to the phase III study were retrieved. Comorbidity was then assessed from 
the medical records using the CIRS-G. The associations between comorbidity scores 
and the outcomes of study 2 were then analyzed. 
 
Methods 
Patient reported HRQoL 
HRQoL was assessed using the EORTC QLQ C30 plus LC13 (Appendix A). The 
patients completed the baseline QLQ before random assignment and then before 
each chemotherapy cycle (weeks 0, 3, 6, and 9) and at follow-up visits (weeks 12, 
20, 28, 36, 44, and 52). The baseline QLQ were handed them by an investigator, the 
following QLQs were sent to the patients from the study office. One reminder was 
mailed if a questionnaire was not returned within 14 days. 
Assessment of response 
The response to the study therapy was assessed according to the RECIST-criteria 
v1.0231 by comparing the baseline CT-scan with the CT-scan performed three weeks 
after the fourth cycle of study treatment: Complete disappearance of all lesions was 
considered to be a complete response (CR), a reduction of the sum or the largest 
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diameters of all measurable lesions of ≥ 30 % was considered to be a partial 
response (PR), an increase in the sum of the largest diameters of all measurable 
lesions of ≥ 20 % was considered to be progressive disease, everything between PR 
and PD was considered to be stable disease (SD). If response assessment was not 
done, the patient was considered to be not evaluable (NE). The RECIST-criteria 
recommends confirmation of response by a repeated CT scan no less than four 
weeks after the first CT scan suggesting response to therapy, but this was not 
mandatory in our study. 
In case of signs of progressive disease, a CT scan was performed at an earlier 
time-point and compared with the baseline CT scan. 
Assessment and grading of toxicity 
Patients underwent laboratory tests before the start of each new cycle of the study 
treatment and on days 8 and 15 of every cycle. More laboratory tests were taken if 
indicated. Hemotological and non-hematological toxicities were assessed at each 
visit and graded using the Common Terminology Criteria of Adverse Events version 
3.0.218 
Definition of time to progression and overall survival 
Time to progression was defined as the time from enrolment on the study until 
progressive disease was proven on CT scans. Survival time was defined as the time 
from enrolment until the time of death. Time of death was recorded from a national 
registry of all citizens in Norway. All patients that did not have progressive disease or 
were alive at one year after the end of enrolment, were censored for the analyses of 
time to progression and overall survival. 
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Assessment of comorbidity 
Assessing comorbidity using the CIRS-G requires training, and a central, 
retrospective analysis was preferred in order to ensure uniform scoring, since the 
CIRS-G has not been in routine use at the participating centres. To ensure 
reproducibility, comorbidity was assessed from hospital medical records only. 
Three physicians, all specialists in oncology, did the scoring (Marit Jordhøy, 
Stein Sundstrøm and Bjørn H. Grønberg). Before scoring, the three physicians 
agreed upon how to interpret the scoring manual for common disorders. 
Two physicians scored comorbidity independently for each patient from the 
hospital medical records. In case of different scores, the two physicians agreed on a 
final score. The most common cause for a different score, was that one of the 
physicians had overlooked disorders mentioned in the medical records. 
 
Statistical considerations 
Sample size estimation for study 1 
“Sensitive” and “refractory” patients were analyzed separately. A two-stage Simon 
design was used to define the sample size in each group. The purpose of this design 
is to avoid exposing more patients than necessary to an experimental therapy that 
may be ineffective. A defined number of patients are enrolled in the first stage. If the 
target number of patients with a response or non-progression is reached, more 
patients are enrolled onto the study before the final analyses are conducted.233 
For “sensitive” patients, a rate of non-progressive disease (non-PD) of 40–
60% was considered to be of clinical significance. 18 patients were to be enrolled in 
the initial phase of inclusion. If ≥8 patients showed non-PD (CR + PR + SD), 28 
additional patients were to be included in this group. The study treatment would be 
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considered worth further investigation in this patient population if ≥23 of 46 patients 
showed non-PD. 
For “refractory” patients, a rate of non-progressive disease of 10–25% was 
considered to be of clinical significance. 21 patients were to be enrolled in the initial 
phase of inclusion. If ≥3 patients responded to the therapy (CR + PR), 29 additional 
patients were to be included in this group. The study treatment would be considered 
worth further investigation in this patient population if ≥8 of 50 patients responded to 
therapy. 
Sample size estimation for study 2 
To detect a difference in HRQoL scores of more than 15 (on a scale from 0 to 100) or 
a difference in 1-year survival rate of more than 11% with an 80% power for a two-
sided significance level at 5%, 190 patients on each treatment arm were required. 
We expected a loss to follow-up of less than 15% and planned to enroll 222 patients 
per arm. 
Definition of the study population for study 3 
There were no statistically significant differences in overall survival, HRQoL or grade 
3-4 adverse events between the treatment arms in the main study. Hence, all 
patients were analyzed as one cohort. 
HRQoL-analyses 
HRQoL scores were calculated according to the EORTC QLQ-C30 scoring 
manual.186 The mean scores and AUCs for the first 20 weeks were then compared 
between the groups of interest. The first 20 weeks included the study treatment 
period plus the first 11 weeks after completion of chemotherapy, and was considered 
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to be the most relevant time period; since we expected that the HRQoL of a large 
proportion of patients would be influenced by progressive disease and/or salvage 
therapy soon after the study treatment ended. 
 Mean scores were calculated from the reported values only. Missing data 
were imputed before calculating AUCs. Missing intermittent scores were replaced 
by the mean value of the two adjacent scores. Last reported value was carried 
forward for other missing values unless the patient died. In those cases, the 
missing values were set to zero from the time of death. A sensitivity test was 
performed using the same method for imputing missing intermittent values, but 
with the last value carried forward for the missing values that followed, even after 
death. The clinically relevant minimum difference in mean HRQoL-scores was 
defined as 10 points (on a scale from 0-100)234. The AUCs for each scale were 
compared between the groups using linear regression adjusting for the baseline 
HRQoL-scores. 
Categorization of comorbidity scores 
A “high severity index” was defined as > 2 and “severe comorbidity” as ≥ one CIRS-G 
score 3 or 4. Within the group with severe comorbidity, patients with ≥ one CIRS-G 
score 4 were defined as having an “extremely severe comorbidity”. In two studies of 
NSCLC, a severity index > 2 and the presence of a CIRS-G score 4 were associated 
with inferior survival.208,209 In addition, we defined “severe comorbidity” since it can be 
difficult to distinguish between a score 3 and a score 4.235 
Survival and toxicity analyses 
Median time to progression and median overall survival were estimated using the 
Kaplan-Meier method. In the univariate analyses, survival data were compared using 
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the log-rank test. The Cox proportional hazards method was used to calculate hazard 
ratios (HR) in the multivariate analyses adjusting for the baseline characteristics 
found to be significant prognostic factors in the univariate-analyses. 
 In the comorbidity-study, we investigated the association between survival and 
well-known prognostic factors: Performance status, stage of disease, gender, 
smoking history and baseline HRQoL – as well as study treatment and the 
comorbidity scores. 
Several baseline HRQoL-scores have been shown to be prognostic factors. 
Based on results from two studies, we considered appetite loss and global QoL to be 
the most important; appetite loss (baseline score > 0) was the most significant 
prognostic factor in a study of stage III NSCLC,202 global QoL was another significant 
prognostic factor in this trial – as well as in a study of chemotherapy in elderly with 
advanced NSCLC.201 The cut-off level for global QoL was defined as in these trials 
(baseline score of 67). Unfortunately, weight loss was only recorded for 215/402 of 
the patients. 
 Toxicity-data were compared using Pearson’s Chi-Square and Fischer’s 
exact tests. 
Significance level 
The significance level was defined at p < .05 for all analyses. 
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Results 
Study 1 
Patients and study treatment 
Thirty-six patients were enrolled onto the study, 34 received study treatment (Figure 
9). Patients were enrolled until the first 12 “sensitive” patients had been evaluated. Of 
these, one had stable disease (SD) and 11 had progressive disease (PD). The 
number of patients with non-PD was inadequate to complete stage two of inclusion of 
“sensitive” patients. At that time, another study of pemetrexed monotherapy in 
recurrent SCLC, had stopped inclusion since too few patients responded to 
treatment.228 Thus, accrual in our study was stopped even though only nine 
“refractory” patients had been enrolled. 
Median age was 61 (range 43–74), 18 (53 %) were men, 25 had sensitive and 
9 refractory disease. Mean number of cycles of pemetrexed was 2.5. One patient (3 
%) had a partial response, three (9 %) had stable disease and 29 (85 %) progressed. 
One patient (3 %) was not evaluable for response or time to progression. Median 
TTP (n = 33) was 7.7 weeks (“sensitive”: 8.4 weeks, “refractory”: 5.1 weeks). Median 
OS (n = 34) was 17.6 weeks (“sensitive”: 22.6 weeks, “refractory”: 15.3 weeks). 
 
Toxicity 
Of grade 3–4 hematologic toxicity, anemia was observed in 2 (6 %) patients, 
leukopenia in 6 (18 %), neutropenia in 9 (27 %) and thrombocytopenia in 3 (9 %). 
Febrile neutropenia occurred in 6 (18% ) patients. There were no treatment related 
deaths. 
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Study 2 
Patients 
Four hundred thirty-six eligible patients were enrolled onto the study; 427 were 
analyzed for HRQoL and 423 for toxicity (Figure 10). 
The baseline characteristics were well balanced between the treatment arms. 
Median age was 65 (range 25-90), 18 % were ≥ 75 years, 58 % men, 88 % had PS 
0-1, 28 % stage IIIB, 50 % adenocarcinoma and 8 % had never smoked. 
 
Study treatment 
The mean number of courses were 3.3 on the pemetrexed-carboplatin arm (PC), 3.1 
on the gemcitabine-carboplatin arm (GC) (p=.037). Significantly more patients in the 
PC-arm completed four cycles (PC: 72 %, GC: 62 %; p=.03), four cycles without 
delays (PC: 58 %, GC: 44 %; p=.004) and four cycles without dose-reductions (PC: 
50 %, GC: 20 %; p<.001). The study-therapy was discontinued due to toxicity in five 
percent of the patients (PC: 4 %, GC: 6 %; p=.5). Slightly more elderly were able to 
complete four cycles without dose-reductions (≥75 years: 38 %, < 75 years: 34 %; 
p=.49). 
 
HRQoL 
The patients completed 2017/2310 (87 %) of the HRQoL-questionnaires (deceased 
patients excluded) during the first 20 weeks. Compliance was similar in the two 
groups (PC: 98 – 80 %, GC: 99 – 78 %).  
There were no clinically relevant or statistically significant differences in 
HRQoL between the treatment arms. The difference in mean score between the 
groups did not exceed 10 points and there were no differences in AUC: Global quality 
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of life (p=.72), nausea/vomiting (p=.55), fatigue (p=.55) or dyspnea (p=.48). In 
addition, the difference in mean scores from baseline through the treatment period 
did not exceed 10 points for either treatment on these four scales (Figure 11). 
 
Figure 11 Mean scores of global quality of life (QoL), fatigue, nausea/vomiting and dyspnea 
according to treatment arm. A higher score of global QoL represents a better QoL, 
whereas a higher symptom score indicates more symptoms. There were no 
statistically significant differences in mean scores or in areas under the curves (AUC) 
between the treatment arms. 	  
	  
 
 
Overall survival 
There was no difference in median overall survival (PC: 7.3 months, GC: 7.0 months; 
p=.63) or one-year survival (PC: 34 %, GC: 31%) between the treatment groups 
(Figure 12). Neither was there any difference in survival when analyzing patients with 
adeno- and large cell carcinomas separately (n=248, PC: 7.8 months, GC: 7.5 
months; p=.77). Multivariate analyses and interaction tests did not reveal any 
significant associations between histology and survival.  
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Among females there was prolonged survival on the PC arm (n=185, PC: 11.0 
months, GC: 7.5 months; p=.022). This survival benefit was also statistically 
significant in a multivariate analysis adjusting for PS and stage of disease (HR 1.43, 
95 % CI 1.03 – 1.99). 
 
Figure 12 Kaplan-Meier survival plot for all patients. PC = pemetrexed plus carboplatin, GC = 
gemcitabine plus carboplatin 
 
 
 
 
 
There was no significant difference in survival between the two treatment arms 
among males (n=251, PC: 6.1 months, GC: 6.6 months; p=.16), PS 0-1 patients 
(n=340, PC: 8.7 months, GC: 7.7 months; p=.51), PS 2-patients (n=96, PC: 4.3 
months, GC: 5.1 months; p=.54) or between elderly and younger patients (n=78, ≥ 75 
years: 7.1 months, < 75 years: 7.3 months; p=.96). 
The multivariate analyses showed that PS (0-1 vs. 2; HR 0.59, 95 % CI 0.46 – 
0.75), stage of disease (IIIB vs. IV; HR 0.78, 95 % CI 0.62 – 0.995) and gender 
(females vs. males; HR 0.77, 95 % CI 0.62 – 0.95) were significant prognostic 
factors. 
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Toxicity 
The GC-patients had significantly more grade 3-4 leukopenia (46 % vs. 23 %, 
p<.001), neutropenia (51 % vs. 40 %, p=.024), thrombocytopenia (56 % vs. 24%, 
p<.001), need for transfusions of red blood cells (43 % vs. 29 %, p=.003) and 
platelets (9 % vs. 3 %, p=.007) (Table 14). There was no significant difference in the 
frequency of thrombocytopenic bleedings (PC: 2 %, GC: 4 %; p=.27), neutropenic 
infections (PC: 8 %, GC 9 %; p=.85) or death from neutropenic infections (PC: 2 %, 
GC: 1 %; p=.67). There was a trend towards more neutropenic infections among 
elderly patients (≥ 75 years: 13 %, < 75 years: 7 %; p=.067). 
 
Table 14 Hematologic toxicity, need for transfusions and use of growth factors (EPO = 
Erythropoietin, GCSF = Granulocyte Colony Stimulating Factor) 
 
 Pemetrexed/ 
Carboplatin 
(n=219) 
 
Gemcitabine/ 
Carboplatin 
(n=217) 
 
 
Toxicity, transfusions and 
growth factors 
 
No. of 
patients 
 
%  
 
No. of 
patients 
 
%  
 
P 
Hematologic toxicity        
    Anemia       .85 
        Grade 3 25 12  25 12   
        Grade 4 2 1  1 1   
    Leukopenia       <.001 
        Grade 3 37 18  76 36   
        Grade 4 10 5  20 10   
    Neutropenia       .024 
        Grade 3 52 25  55 26   
        Grade 4 31 15  51 25   
    Thrombocytopenia       <.001 
        Grade 3 28 13  67 32   
        Grade 4 24 11  51 24   
Transfusions        
    Blood 59 29  88 43  .003 
    Platelets 6 3  19 9  .007 
Use of growth factors        
    EPO 3 1  1 1   
    GCSF 1 1  0 0   
 
The most common other grade 3-4 adverse events during the treatment period 
were infections (9 % in both arms, p=.98) and nausea (GC: 4 %, PC: 3 %, p=.43) 
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(Table 15). There was no significant difference in the frequency of any single grade 
3-4 non-hematological adverse event, but more patients on the GC arm had ≥ 1 
grade 3-4 adverse event (28 % vs. 19 %, p=.037). 
 
Table 15 Non-hematologic grade 3 or 4 adverse events during the study treatment period 
 
 
 Pemetrexed/ 
Carboplatin 
(n=219) 
 
Gemcitabine/ 
Carboplatin 
(n=217) 
 
 
Grade 3 or 4 Adverse events 
 
No. of 
patients 
 
%  
 
No. of 
patients 
 
%  
 
P 
Neutropenic infection 17 8  18 9  .85 
Infections without neutropenia 19 9  19 9  .98 
Nausea 6 3  9 4  .43 
Thrombocytopenic bleedings 5 2  9 4  .27 
Deep venous thrombosis 0 0  3 1  .12 
Lung embolism 0 0  4 2  .06 
Acute myocardial infarction 1 1  2 1  .62 
Mucositis 2 1  0 0  .50 
Other 4 2  12 6  .04 
        
Any grade 3 or 4 adverse events 41 19  60 28  .037 
 
 
 
Poststudy treatment 
Thirty-two percent of the patients received second-line therapy (chemotherapy: 24 %, 
EGFR-TKIs: 8 %), 7 % received third-line therapy and 41 % had palliative 
radiotherapy. There was no difference in post-study treatment between the treatment 
arms. More females than males had second-line therapy (38 % vs. 26 %, p=.004) 
while there was no difference between the treatment arms among females (PC: 42 
%, GC: 35 %; p=.34). 
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Study 3 
Patients 
Of the 436 patients analyzed in Study 2, 402 were eligible for Study 3 (Figure 10). 
Median age of all patients was 65 years, 36 % were ≥ 70 years, 18 % were ≥ 75 
years, 58 % men, 79 % had PS 0-1 and 29 % stage IIIB. The baseline characteristics 
were well balanced between the patients with high and low severity index. There 
were more elderly, males and stage IIIB among the patients with severe comorbidity 
than among patients with less comorbidity. 
 
Study treatment 
There was no significant difference in the mean number of cycles administered 
between patients with or without severe comorbidity (3.2 vs. 3.5: p=.05) and the 
proportions of patients who completed all four cycles were similar (65 % vs. 73 %; 
p=.08). Fewer of the patients with severe comorbidity received second-line systemic 
therapy (27 % vs. 26 %; p=.04) and post-study radiotherapy (35 % vs. 48 %; p=.01). 
There were no differences in study-treatment or post-study therapy depending 
on the presence of extremely severe comorbidity or a high severity index. 
 
Comorbidity 
The median total CIRS-G score was 7 (range 0-17). Only three patients had no 
comorbidity, 8 % had no CIRS-G score > 1, 49 % had severe comorbidity (≥ one 
CIRS-G score 3-4), 9 % had extremely severe comorbidity (≥ one CIRS-G score 4) 
and 15 % had a high severity index (> 2). Most CIRS-G scores 3 and 4 were 
registered on the respiratory (25 %), vascular (10 %) and heart (10 %) scales; 68 % 
of the patients with severe comorbidity had disorders on these scales only. 
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Survival 
There were no significant differences in survival when comparing patients with and 
without severe comorbidity (6.9 vs. 8.1 months; p=.34) (Figure 13), with and without 
extremely severe comorbidity (6.7 vs. 7.7 months; p =.88) and patients with a high 
severity index with those having a low severity index (8.4 vs. 7.4 months; p=.76). Nor 
did comorbidity influence survival among the patients with PS 2 or the elderly ≥ 75 
years. 
PS (p=.001), gender (p=.02), baseline global QoL (p=.004) and appetite loss 
(p=.006) were significant prognostic factors in the univariate survival analyses. 
According to the multivariate survival analyses, PS (0-1 vs. 2: HR .74; 95 % CI .56 - 
.96) and gender (women vs. men: HR .76; 95 % CI .61 - .96) but none of the 
comorbidity-scores were significant, independent prognostic factors. 
 
Figure 13 Survival according to the presence of severe comorbidity (defined as ≥ one CIRS-G 
score 3-4) 
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Toxicity 
The patients with severe comorbidity developed significantly more grade 3-4 
thrombocytopenia than those with less comorbidity (46 % vs. 36 %; p=.03), but did 
not experience more thrombocytopenic bleedings (3 % vs. 4 %; p=.65). The 
frequency of grade 3-4 neutropenia was comparable (48 % vs.  42 %; p=.16) 
whereas significantly more neutropenic fevers (12 % vs. 5%, p=.01) and all deaths 
from neutropenic infections  (3 % vs. 0 %, p=.03) were observed among the patients 
with severe comorbidity (Table 16). When looking at the subgroup of patients < 75 
years, the same pattern of differences in toxicity depending on the presence of 
severe comorbidity were observed. 
 
Table 16 Toxicity according to the presence of severe comorbidity (defined as ≥ one CIRS-G 
score 3-4) 
 
  No severe comorbidity 
(n=212)  Severe comorbidity (n=198)  
Adverse events  No. of Pts. %  No. of Pts. % p 
Grade 3-4 hematologic toxicity        
   Anemia  26 13  26 13 .85 
   Leukopenia  67 33  68 35 .65 
   Neutropenia  86 42  94 49 .16 
   Thrombocytopenia  74 36  92 47 .03 
Grade 3-4 non-hematologic adverse events        
   Infection without neutropenia  14 7  20 10 .22 
   Neutropenic infection  10 5  23 12 .01 
   Nausea  10 5  5 3 .22 
   Thrombocytopenic bleeding  8 4  6 3 .65 
   Other  12 6  16 8 .36 
   One or more adverse event  45 22  49 25 .46 
Death from adverse events        
   Neutropenic infection  0 0  5 3 .03 
   Infection  4 2  4 2 1.0 
   Other  1 1  5 3 .11 
   Total  5 2  14 7 .03 
 
 
The patients with severe comorbidity who developed neutropenic fevers had 
disorders on the following CIRS-G scales: Heart (n=8), vascular (n=7), respiratory 
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(n=11), genitourinary (n=1) and psychiatric (n=1). The patients who died from 
neutropenic infections had severe comorbidity in the respiratory (n=4) and the 
vascular system (n=1). 
Extremely severe comorbidity or a high severity index did not predict more 
grade 3-4 adverse events. 
 
Health related quality of life 
Compliance of the HRQoL-questionnaires during the first 20 weeks was 88 %, and 
was similar in all subgroups. 
The patients with severe comorbidity consistently reported poorer HRQoL on 
the scales defined as the primary HRQoL-endpoints, and their mean scores 
deteriorated slightly more than in the patients with less comorbidity (Figure 14). 
However, the difference in mean score exceeded a clinically significant difference (10 
points) only at one time point (week 12) and only on three of four scales (global QoL, 
fatigue and dyspnea). 
When comparing AUCs, the patients with severe comorbidity had significantly 
worse global QoL (p=.01), more fatigue (p=.001) and dyspnea (p=.01), whereas 
nausea/vomiting was comparable to what the patients with less comorbidity reported 
(p=.31). The sensitivity tests confirmed the difference in global QoL (p=.002), but not 
in fatigue (p=.48), nausea/vomiting (p=.86) or dyspnea (p=.28). 
On the other HRQoL-scales, there was a trend towards worse physical and 
role functioning among the patients with severe comorbidity. Otherwise, no 
differences were registered. Extremely severe comorbidity or a high severity index 
did not predict significant differences in HRQoL during study treatment. 
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Figure 14 Mean scores for the primary HRQoL-endpoints according to the presence of severe 
comorbidity (defined as ≥ one CIRS-G score 3-4) 
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Discussion 
Tolerability of pemetrexed 
The studies demonstrate that pemetrexed is well tolerated by lung cancer patients; 
both as high-dose monotherapy and at the standard dose in combination with 
carboplatin. This has also been observed in other studies of similar patient 
populations.11,228,229 
 
High-dose pemetrexed 
The number of patients in the phase II study of high-dose pemetrexed monotherapy 
is limited, but since the frequency of grade 3-4 toxicity was similar in two other 
studies of pemetrexed monotherapy in recurrent SCLC, it appears that the compound 
was well tolerated; both in standard- and high-dose. Furthermore, the frequency of 
hematological toxicity was much lower than in two previous studies of two commonly 
used regimens for this patient population; topotecan141,142 and CAV 
(cyclophosphamide, doxorubicin and vincristine) (Table 14).142 
 
Table 14 Hematological toxicity in three studies of pemetrexed in recurrent SCLC and in two 
studies of other second-line therapy in SCLC 
 
   Grade 3-4 toxicity 
  Regimen 
 
n 
 
Anemia 
 
Neutropenia 
 
Thrombo-
cytopenia 
 
Febrile 
neutropenia 
Ardizzoni141 Topotecan 1.5 mg/m
2 IV day 
1-5 every 3 weeks 92 12 % 75 % 30 % 6 % 
von 
Pawel142 
Cyclophosphamide 1000 
mg/m2, Doxorubicin 45 
mg/m2, Vincristine 2 mg IV 
every 3 weeks 
104 19 % 83 % 14 % 26 % 
 Topotecan 1.5 mg/m
2 IV day 
1-5 every 3 weeks 107 42 % 86 % 56 % 28 % 
Jalal228 Pemetrexed 500 mg/m
2 IV 
every 3 weeks 43 9 % 12 % 12 % 10 % 
Socinski229 Pemetrexed 500 mg/m
2 IV 
every 3 weeks 56 0 % 16 % 3 % 0 
 Pemetrexed 900 mg/m
2 IV 
every 3 weeks 65 3 % 9 % 5 % 1 % 
Grønberg236 Pemetrexed 900 mg/m
2 IV 
every 3 weeks 34 6 % 27 % 9 % 18 % 
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From the three studies of pemetrexed, it appears that in supplemented patients, 
there is no significantly increased toxicity from the high dose. This has also been 
observed in studies comparing standard- and high-dose pemetrexed in recurrent 
NSCLC237,238 and as first-line therapy of advanced breast cancer.239 
 
Pemetrexed plus carboplatin 
The patients who received the pemetrexed-combination were able to receive slightly 
more cycles of chemotherapy, more of these patients were able to complete all 
preplanned four cycles and fewer of them had dose-reductions or delays of the 
chemotherapy than the patients on the gemcitabine-arm. They reported similar 
HRQoL and since fewer of them had a grade 3-4 hematological toxicity, they needed 
less transfusion of red blood cells and platelets – and in theory they had a lower risk 
for complications from the chemotherapy. However, there were no significant 
differences in the frequency of any single grade 3-4 non-hematological toxicity, 
though more patients on the gemcitabine-arm had one or more grade 3-4 adverse 
events during the study treatment period. 
Results from the only other phase III study comparing pemetrexed plus a 
platinum compound with a standard combination in the first-line therapy of advanced 
NSCLC confirms that pemetrexed is well tolerated in this patient population.11 In this 
study, pemetrexed plus cisplatin caused less grade 3-4 hematological toxicity than 
gemcitabine plus cisplatin. Furthermore, in this study, fewer patients on the 
pemetrexed-arm developed febrile neutropenia and alopecia; whereas they 
experienced more nausea. 
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Efficacy of pemetrexed in lung cancer 
The studies suggest that pemetrexed does not have a role in the treatment of SCLC, 
whereas pemetrexed plus carboplatin may be administered as first-line 
chemotherapy in advanced NSCLC. Other studies confirm the lack of efficacy of 
pemtrexed in SCLC, whereas other studies have demonstrated that pemetrexed may 
be superior to other regimens in the treatment of non-squamous NSCLC. 
 
Small-cell lung cancer 
Results from our study suggest that very few patients with recurrent SCLC respond 
to pemetrexed monotherapy. The number of patients analyzed is limited, but this is 
due to the fact that enrolment was ended according to predefined stopping rules. 
However, two other studies of pemetrexed monotherapy confirm the low response 
rates to pemetrexed in recurrent SCLC..228,229 Both studies enrolled sensitive and 
refractory patients. In one study,228 all patients received standard-dose pemetrexed 
(500 mg/m2) while in the other study,229 patients received either standard-dose or 
high-dose pemetrexed. In total, 159 patients were evaluable for response in these 
two studies. PR was observed in 3 patients (1.9 %) and SD in 24 patients (15 %). In 
contrast, response rates of 18-24 % have been observed after second-line therapy 
with topotecan and CAV (cyclophosphamide, adriamycin and vincristin).141,142,240 
A phase II trial demonstrated similar efficacy of pemetrexed in combination 
with carboplatin and cisplatin as previously reported for standard therapy (etoposide 
plus cisplatin).165 Response rates were 35-40 % and OS 7.6-10.4 months. The 
carboplatin combination appeared to be more effective than the cisplatin 
combination, and a phase III study comparing pemetrexed plus carboplatin with the 
reference regimen, carboplatin plus etoposide, was conducted.241 Enrolment on this 
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study was closed after a preplanned interim-analysis revealed that the pemetrexed 
combination was significantly inferior to the etoposide-combination with respect to 
response rates, progression free survival and overall survival. 
 Based on the results from these trials, the overall conclusion is that 
pemetrexed does not have a role in the treatment of SCLC. 
 
Table 15 Response rates, time to progression and overall survival for pemetrexed monotherapy 
compared with results from two other studies of second-line therapy of small-cell lung 
cancer 
 
 Regimen Refractory/Sensitive patients n RR TTP OS 
Ardizzoni141 Topotecan 1.5 mg/m
2 IV day 
1-5 every 3 weeks Refractory 47 6 % 4.7 m 
  Sensitive 45 38 % 
2.8 m 
6.9 m 
von 
Pawel142 
Cyclophosphamide 1000 
mg/m2, doxorubicin 45 
mg/m2, vincristine 2 mg IV 
every 3 weeks 
- 104 18 % 2.8 m 5.8 m 
 Topotecan 1.5 mg/m
2 IV day 
1-5 every 3 weeks - 107 24 % 3.0 m 5.7 m 
Jalal228 Refractory 23 4 % 1.2 m 2.7 m 
 
Pemetrexed 500 mg/m2 IV 
every 3 weeks Sensitive 20 5 % 1.3 m 4.4 m 
Socinski229 Refractory 25 0 % 1.5 m 3.2 m 
 
Pemetrexed 500 mg/m2 IV 
every 3 weeks Sensitive 15 0 % 1.3 m 6.1 m 
 Refractory 40 0 % 1.2 m 2.5 m 
 
Pemetrexed 900 mg/m2 IV 
every 3 weeks Sensitive 41 3 % 1.4 m 4.2 m 
Grønberg236 Refractory 9 11 % 1.2 m 3.5 m 
 
Pemetrexed 900 mg/m2 IV 
every 3 weeks Sensitive 25 0 % 1.9 m 5.2 m 
 
 
Dose-level of pemetrexed 
The uniform results from all the phase II trials of pemetrexed in recurrent SCLC 
suggest that the higher dose does not improve efficacy of pemetrexed. This is poorly 
investigated since almost none of the patients responded to the treatment, but 
corresponds well with the results from trials in NSCLC and breast cancer, where 
increasing the pemetrexed dose failed to improve efficacy.237-239 
 
Non-small-cell lung cancer 
Our study suggests that pemetrexed plus carboplatin provide the same survival 
benefit as a standard regimen in first-line therapy of advanced NSCLC. In another 
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study, the overall survival for patients receiving pemetrexed plus cisplatin was similar 
as for patients receiving gemcitabine plus cisplatin (10.3 vs. 10.3 months; HR .94, 95 
% CI .84 - 1.05).11 
 The survival data are similar to what we have observed in previous trials of 
advanced NSCLC.38,39 The overall survival is shorter than in other trials of 
gemcitabine/platinum combinations in advanced NSCLC,242 whereas the overall 
survival for patients with a PS of 0 to 1 is comparable to what was observed in these 
studies. The most likely explanation is the relatively high proportion of patients with 
PS 2 in our trial (22%); PS 2 is a known negative prognostic factor.24 
In a phase III study, pemetrexed demonstrated similar efficacy and a more 
favorable toxicity profile than docetaxel in second-line therapy of NSCLC.156 A recent 
study has demonstrated a substantial survival benefit for maintenance pemetrexed 
therapy over BSC alone in patients who did not progress after four cycles of 
platinum-doublet chemotherapy.79 Overall, the patients receiving pemetrexed had a 
significant survival benefit of 2.8 months (13.4 vs 10.6 months; p=.012), though the 
benefit was limited to patients with non-squamous histology (15.5 vs. 10.3 months; 
p=.002). These trials confirm that pemetrexed has a role in the treatment of NSCLC 
and mainly in patients with non-squamous histology. 
Subgroup analyses 
In general, there is a great interest in trying to characterize the patients who have the 
greatest chance for a clinically relevant benefit of chemotherapy; the survival 
prolongation is limited and side-effects that may provide a poor HRQoL – and in 
some cases may be life-threatening – are not uncommon. 
 Conducting subgroup-analyses is controversial. It can provide important 
additional information and define research questions for further trials – and ethically it 
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seems optimal to try to answer as many questions as possible once patients have 
been exposed for experimental therapy. Not to mention that conducting clinical trials 
take a lot of efforts. On the other hand, the statistical power for such analyses is 
limited and the risk of finding associations by chance is high. Thus, subgroup 
analyses should be pre-specified with respect to what analyses to conduct and how 
to perform them. 
 When it comes to the main categorization of lung cancer patients, SCLC vs. 
NSCLC, these subgroups were investigated separately in two defined study 
populations. The study of the associations between comorbidity and survival, toxicity 
and HRQoL were predefined, whereas the other subgroup-analyses conducted in 
study 2 were not. However, they were conducted since there appeared to be an 
association between histology and efficacy of pemetrexed in other studies. 
 
The association between histology and efficacy of pemetrexed in NSCLC 
Subgroup-analyses of several studies of pemetrexed in NSCLC, have revealed that 
pemetrexed may be more effective in patients with non-squamous tumors and may 
have inferior efficacy in squamous cell carcinomas when compared with standard 
regimens; both in first-11 and second-line therapy243 and as maintenance therapy in 
patients who did not progress after four cycles of platinum-doublet first-line therapy 
(Table 15).79 Based on these data, pemetrexed is now registered for the use in 
patients with non-squamous histology only. 
In contrast, there were no associations between histology and survival in our 
study population in univariate, multivariate or interaction tests. There was, however, a 
significantly longer survival on the pemetrexed-arm among women. At the present 
time, there are no obvious explanations for these findings. To our knowledge, there 
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are no other reports of any association between gender and efficacy of any specific 
cytotoxic therapy, though in the phase III study of pemetrexed plus cisplatin as first-
line therapy of NSCLC, there was also a trend towards a survival benefit of 
pemetrexed among women.11 
 
Table 15 Efficacy of pemetrexed according to histology 
 Indication Regimen Non-squamos histology p 
Squamous cell 
carcinoma p 
Scagliotti11 First-line Pemetrexed + 
cisplatin 11.8 mo  9.4  
  Gemcitabine 
+ cisplatin 10.4 mo .005 10.8 .050 
Grønberg244 First-line Pemetrexed + 
carboplatin 7.8 mo    
  Gemcitabine 
+ carboplatin 7.5 mo .77   
Ciuleanu79 Maintenance Pemetrexed 15.5 mo  9.9 mo  
  BSC 10.3 mo .002 10.8 mo .68 
Hanna156,243 Second-line Pemetrexed 9.3 mo  6.2 mo  
  Docetaxel 8.0 mo .048 7.4 mo .018 
 
 
 
Possible explanations for the varying efficacy of pemetrexed in subgroups of 
lung cancer patients 
The main mechanism of action of pemetrexed is believed to be inhitbion of TS.  In 
case, it seems reasonable that pemetrexed is most effective against tumors with low 
TS-level. There are indications that tumors with low TS-level have a higher response 
rate to pemetrexed therapy in breast,245colon,246 and lung cancer.247 Results from 
two studies suggest that the TS-level is higher in squamous-cell carcinomas than in 
adeno- and large cell carcinomas.248,249 This may explain why pemetrexed is mostly 
active in non-squamous NSCLC. 
Immunohistochemistry analyses of patients enrolled onto the phase III trial of 
pemetrexed plus carboplatin as first-line therapy of SCLC, revealed that low TS-
expression was correlated with OS in the etoposide-arm, but there was no such 
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association with OS in the pemetrexed-arm.250 A recent report suggests that the TS-
level in SCLC is high251 and higher than observed in any subgroups of NSCLC. 
There are no obvious explanations for why there was no histology-effect or 
why there was a gender-specific survival benefit for pemetrexed in our trial.  
The influence of comorbidity on outcomes in patients with advanced NSCLC 
Results from other studies of the influence of comorbidity on survival in advanced 
NSCLC are not uniform. In one study,210 comorbidity was associated with inferior 
survival, but the investigators analyzed a mixed cohort of patients with stage I who 
had undergone surgical resection and patients with advanced disease that received 
platinum-based chemotherapy. Unfortunately, the influence of comorbidity for the 
groups was not reported separately. It is also noteworthy that 69 % of the patients did 
not have any comorbidity – while in our study, only three patients did not. One reason 
can be that comorbidity was assessed using the Charlson index - which is less 
sensitive than the CIRS-G.235 
In another study, there was no influence of comorbidity on survival in the 1005 
patients with advanced lung cancer.196 Since the analysis was based on a hospital 
registry, there were no data on what therapy these patients had received. In two 
small studies, there were no association between comorbidity and overall 
survival.201,211 
Two studies have looked at the association between comorbidity and toxicity 
from therapy. The largest study analysed 1255 patients.210 However, comorbidity was 
assessed using the Charlson index and 69 % of patients did not have any 
comorbidity. Toxicity for patients with advanced disease was not reported separately. 
The main findings were that patients with comorbidity had more infections, 
complications in the gastro-intestinal tractus, rash and nausea. In a small trial 
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(n=46),211 no association between comorbidity and toxicity from platinum-based 
therapy was found. 
No studies have looked at the association between comorbidity and impact on 
HRQoL in NSCLC. However, a study of head & neck cancer patients demonstrated 
that radiotherapy did not have more impact on HRQoL with severe comorbidity than 
in other patients.252 
Elderly patients 
There is no consensus on the optimal therapy in elderly. Some recommend that 
elderly should receive the same treatment as younger patients253 – whereas others 
suggest that they should receive monotherapy or non-platinum combinations.36 It is a 
problem that elderly90-92 – especially those with comorbidity194 – are 
underrepresented or excluded from the clinical trials that treatment recommendations 
are based upon. 
Results from a previous trial, have led the NCLG to recommend a dose-
reduction of 25 % to all patients ≥ 75 years.39 This may seem unnecessary, since the 
Cockroft-Gault formula takes into consideration age.70 However, there are a lot of 
uncertainties regarding calculation of doses of chemotherapy. The Cockroft-Gault’s 
formula is an estimation of renal clearance and Calvert’s formula was derived from 
only 18 patients. Exactly how to calculate the optimal dose in patients with low 
muscle mass and hence a potentially artificially low serum-creatinine is poorly 
explored. In addition, pemetrexed and gemcitabine doses are calculated from an 
estimation of body surface area (BSA). Despite several attempts, no better way of 
individualizing doses of chemotherapy has entered clinical practice. Recent studies 
have suggested that adjusting for body composition, particularly the proportion of 
muscle-mass, may be a method for defining a more optimal dose of 
  84 (127) 
chemotherapy.254-256 Body composition varies between cancer patients, and it has 
been demonstrated that elderly in general have lower muscle mass.257,258 
In our study, the OS for elderly patients was similar as for younger. They had 
as many dose-reductions as the younger patients and tended to have more 
neutropenic infections. In general, elderly have more comorbidity and study 3 
suggests that the presence of severe comorbidity was associated with a higher risk 
of acquiring infections when neutropenic. These observations suggest that the elderly 
patients received an adequate dose of chemotherapy. However, studies comparing 
monotherapy, non-platinum combinations, standard platinum-combinations and 
dose-reduced platinum-combinations – and preferably taking into account 
comorbidity and body composition - in elderly patients with advanced NSCLC are 
needed to define the optimal therapy for this large group of patients. 
Limitations to the studies 
Limitations to study 1 
A possible limitation to our study is that there was no central review of CT scans for 
response-evaluation. In addition, the protocol did not warrant confirmation of 
responses. No central pathology review was conducted; since SCLC and NSCLC 
have been treated differently for such a long time, we presumed that all pathology 
departments had good diagnostic procedures to differ between these two entities.  
 There are no reasons to believe that any of these limitations have influenced 
the conclusion of our trial, since there was almost no activity of pemetrexed and 
since our results have been confirmed in two other trials. Furthermore, according to 
the recently revised guidelines for response evaluation in solid tumors – the RECIST 
v1.1259 – confirmation of response is only required for trials with response primary 
endpoint, but not in randomized studies. 
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One can question whether it is optimal to conduct a one-armed phase II study 
as long as there has been a long tradition of administering second-line therapy in 
SCLC. When there are consistent historical data for comparison from several 
previous trials available, this may be appropriate. The main reason for conducting a 
one-armed trial is that it is easier to conduct – especially when the number of patients 
eligible is limited. However, one should not underestimate the effect of better 
procedures for diagnosis and staging of cancer, changing methods for assessing 
efficacy and improved BSC over the years; all of these factors may diminish the 
value of historical controls. When the efficacy of an experimental drug is as low as in 
this study, the choice of design probably does not influence the interpretation of the 
results. But when the efficacy is as promising as in the phase II study of pemetrexed 
plus carboplatin or cisplatin as first-line therapy of ED SCLC,165 it is not uncommon to 
move on to a phase III study – which happened in this case. Hence, many patients 
received an inferior therapy – which, as the authors comment, may have been 
avoided if the phase II study had included a randomized comparison with a standard 
regimen.241 
Limitations to study 2 
There were no significant differences in HRQoL between the treatment arms, 
although significantly more patients on the gemcitabine-arm experienced one or 
more grade 3-4 non-hematological toxicity. One interpretation is that the objectively 
measured toxicity did not reduce the patient’s HRQoL. Another explanation may be 
that it is well recognized among cancer patients that chemotherapy can lead to 
toxicity, and if the adverse events did not exceed the expectations, they may not 
automatically lead to a perception of a reduced HRQoL 
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Another possible explanation is that the timing of the assessment was not 
optimal to detect a difference in HRQoL due to treatment related toxicity. In our study 
- as in other, previous trials - HRQoL was assessed immediately before a new cycle 
of chemotherapy was administered. Previous studies have shown that the level of 
side-effects due to therapy varies during the cycle, and is most pronounced during 
the first week after the administration of chemotherapy.260 Thus, it is possible that 
most of the adverse events had resolved when the patients answered the QLQs. It is 
worth noticing that there were more delays of cycles of chemotherapy on the 
gemcitabine-arm – mostly due to hematological toxicity – and it is possible that these 
patients then had more time to recover from adverse events than on the pemetrexed 
arm. 
The fact that there were no significant differences in cancer-related symptoms 
is more easily explained, since the efficacy of the regimens appeared to be similar. 
For this comparison, the timing of assessment of HRQoL appears to have been 
optimal, as the QLQs were probably answered during the part of each cycle when the 
side-effects from the therapy were the least pronounced. 
Unfortunately, we did not register the presence of brain metastases and 
malignant pleural fluid and weight loss over the last months; all significant prognostic 
baseline characteristics. An imbalance for these factors could potentially influence 
the survival analyses. At the time of study enrolment, TNM version six was used. In 
the seventh revision of the TNM, the description of malignant pleural fluid has been 
changed from T4 to M1 indicating that it is a poorer prognosis than previously 
believed.19 In general, the presence of brain metastases is a negative prognostic 
factor, the median overall survival is approximately 4 months,261,262 though some 
subgroup analyses suggest that fit patients with asymptomatic brain metastases who 
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are found eligible for clinical trials with relatively strict eligibility criteria appear to have 
the same outcome as other patients.261,263 In case, the performance status may be of 
greater importance than the presence of brain metastases, and the two treatment 
arms in our study were very well balanced for all baseline characteristics registered. 
Another limitation is that we did not register RR, TTP or PFS. This is resource 
demanding, and at the time we started the study, the use of salvage therapy was 
limited. One can argue that these are surrogate markers for efficacy, and that HRQoL 
and overall survival are the most important outcomes for each patient. In this trial, 
more patients received salvage therapy than in previous trials conducted by the 
NLCG - which may have masked differences in the effect of the first-line therapy. 
Then again, there were no significant differences in the number of patients who 
received salvage therapy between the treatment arms or the time to start of second-
line therapy (pemetrexed/carboplatin: 4.7 months, gemcitabine/carboplatin 4.6 
months; p=.90). 
Since the administration schedule and infusion time are different between 
gemcitabine and pemetrexed, a blind study was not possible to conduct. 
 
Dosage of chemotherapeutic compounds 
The gemcitabine-dose of 1000 mg/m2 on day 1 & 8 of every cycle, was introduced in 
Norway through a former trial comparing vinorelbine plus carboplatin with 
gemcitabine plus carboplatin in advanced NSCLC.39 The dose-level is in the lower 
range of what is recommended, but there are no established differences in efficacy 
within the range of 1000-1250 mg/m2.242 
In two of the phase II trials investigating the efficacy of pemetrexed plus 
carboplatin, a carboplatin dose of AUC=6 was administered.72,264 Based on the 
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frequency of hematological toxicity in previous studies,38,39 the NLCG decided to 
maintain the dose of AUC=5 also for this study. In our study, significantly more 
hematological toxicity was observed than in the phase II trials, suggesting that the 
carboplatin-dose was adequate. Most likely, the cause for the difference in 
hematological toxicity is the wide eligibility criteria in our study. 
Since the dosage of chemotherapy was defined to be suitable for a relatively 
unselected population of patients, one can argue that the dose-levels may be 
suboptimal for the most fit patients. However, OS for the patients who completed all 
preplanned four cycles (pemetrexed/carboplatin: 11.0 months, 
gemcitabine/carboplatin: 10.3 months; p=.93) was similar to what was observed in 
the overall population in the phase III trial of pemetrexed plus cisplatin (10.3 
months).11 These patients were the ones who were most similar to the patients 
enrolled onto the latter study. 
 
Limitations to study 3 
We did not collect information about the patients diagnosed with advanced NSCLC 
that were not enrolled onto the trial. Thus, we cannot say whether some patients 
were excluded from the study due to comorbidity even if they fulfilled the eligibility 
criteria per se. 
There was clearly a variation in how much information about co-existing 
disorders that was collected in the hospital medical records and there is no way to 
ensure that all comorbidities have actually been registered. On the other hand, this 
limitation will apply for most studies of comorbidity and one can argue that our source 
data are representative for what was considered vital information in the clinic. In 
addition, the frequency of severe comorbidity was similar to what has been observed 
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in other studies of comorbidity in NSCLC190,191,201 and missing information on mild 
comorbidity would primarily influence the Severity Index – which for this reason may 
be a less reliable CIRS-G score. To minimize this variation, studies have to be 
conducted only in sites where specially trained personnel do the assessment of 
comorbidity. 
There was a numerical difference in survival depending on the presence of 
severe comorbidity and one can argue that the study was underpowered. However, 
in the studies on lower stage NSCLC that demonstrated a significant prognostic 
influence of comorbidity on survival, fewer patients were entered.208,209 In addition, 
other, well-known, easy-to-assess baseline characteristics were significant 
prognostic factors also in our study population. 
The instrument for measuring comorbidity, the CIRS-G, was developed in 
1991.217 Some of the scores are set depending upon the number of medications for 
the individual co-existing disorder. It may be that guidelines now recommend the 
daily use of a higher number of drugs for conditions that are common in lung cancer 
patients – such as cardiovascular and respiratory disease. In case, a high score may 
now be set in a higher proportion of patients than earlier. This could result in patients 
with relatively mild comorbidity being classified as having severe comorbidity. There 
may also be variation in guidelines for the treatment of co-existing disorders between 
countries. 
A more extensive characterization of the patients may be better for 
categorizing patients than comorbidity assessment alone.265,266 However, measuring 
comorbidity is challenging, and an even more comprehensive, multidimensional 
geriatric assessment will be difficult to perform in a multicentre trial. 
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Strengths of the studies 
The main strength is that the patients enrolled onto the NSCLC-study are similar to 
the patients seen in the everyday clinic. During the study enrolment period, 2281 new 
cases of NSCLC were diagnosed in Norway (all stages of disease). Hence, 20 % of 
all patients were enrolled onto the study. 
 Unfortunately, the Norwegian cancer registry does not accurately register the 
TNM-stage of patients, but it has been estimated that more than 50 % of patients are 
diagnosed with advanced disease.37 Some of these patients will be eligible for 
curative radiotherapy, some will receive palliative radiotherapy – and some will have 
too poor performance status or organ function to receive platinum-based 
chemotherapy. If we estimate that 50 % of patients have advanced disease and that 
20 % are not candidates for platinum-based chemotherapy, 40-50 % of eligible 
patients nationwide were enrolled onto our study. 
Median age (68 years) is close to the median age at diagnosis in the 
Norwegian population (approximately 70 years),2 22 % had PS 2, 36 % were ≥ 70 
years and 18 % ≥ 75 years. In addition, patients with severe comorbidity, brain 
metastases or malignant pleural fluid were allowed – patients who are often excluded 
from clinical trials. 
Based on general knowledge about immigration in Norway and the names of 
the patients enrolled onto the study, it is safe to assume that all patients were 
Caucasians and ethnic Norwegians. This ensures genetic homogeneity; but may also 
be a limitation to the trial if Norwegians metabolize the investigated cytotoxic 
compounds differently than other ethnic groups. 
 Another strength is that comorbidity was assessed from hospital medical 
records, the most valid source documentation of a patient’s health status. This 
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ensures reproducibility. The assessment of comorbidity was done by trained 
personnel, and by three physicians only. This ensured good inter- and intra-rater 
reliability. 
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Conclusions 
• Very few patients with recurrent SCLC respond to high-dose pemetrexed 
monotherapy, though the therapy appeared to be well tolerated. 
 
• Patients with advanced NSCLC who receive pemetrexed plus carboplatin as first-
line chemotherapy, have similar HRQoL and survival, less hematological toxicity 
and less need for supportive care than patients who receive a standard regimen, 
gemcitabine plus carboplatin. 
 
• The presence of co-existing disorders does not influence survival in patients with 
advanced NSCLC receiving chemotherapy. In general, patients with severe 
comorbidity do not have more toxicity from such therapy, but they appear to have 
a higher risk of infections when neutropenic. Overall, they also report a poorer 
HRQoL, but their HRQoL do not deteriorate more than in other patients during 
chemotherapy. 
 
Implications of the results and topics for future 
research 
The result from ours – and other studies – show that the efficacy of pemetrexed in 
SCLC-patients is very low and lower than in previous studies of other regimens. 
Thus, pemetrexed should not be administered to SCLC-patients outside clinical trials. 
The only rationale for further studies would be that one is able to identify 
characteristics of patients who have a high chance for responding to the therapy. 
Preliminary results from a pharmacogenomic study of patients who received 
pemetrexed plus carboplatin as first-line therapy of ED SCLC, suggest that there 
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may be genetic markers characterizing the patients who responded to either 
pemetrexed plus carboplatin or etoposide plus carboplatin.250 Since so few 
SCLC-patients respond to pemetrexed, such studies have to be conducted through 
an international collaboration. 
  Our study – together with results from another study – demonstrate that 
pemetrexed plus a platinum compound is an attractive alternative in the first-line 
treatment of advanced NSCLC. Based on results from other studies, pemetrexed is 
now approved for the treatment of non-squamous tumors, both as first- and second-
line therapy. No association between histology and efficacy was revealed in our 
study, but there appeared to be a benefit for the pemetrexed combination among 
women. This finding and the apparent histology effect demonstrated in several other 
studies, have lead to the initiation of a biomarker study of our patients. All available 
biopsies have been collected and will be analyzed to see if there are associations 
between biomarker status and outcomes of the study therapy.  
When it comes to clinical trials, the NLCG is currently planning a study that will 
further explore the efficacy of maintenance pemetrexed after first-line chemotherapy 
in advanced NSCLC. A main feature of this trial, will be to assess 
cachexia/sarcopenia as a prognostic factor for survival and a predictive factor for 
toxicity and deterioration of HRQoL from chemotherapy.  
The ability to identify the patients with the highest risk of neutropenic infections 
would have great clinical implications. The NLCG has performed several studies in 
advanced NSCLC with more or less similar eligibility criteria. Merging the databases 
from these studies and then do a case-control study could be a way of gaining further 
evidence for the apparent association between comorbidity and neutropenic 
infections. If such studies confirm the results from the present analysis, studies on 
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prophylactic use of antibiotics and granulocyte colony stimulating factors should be 
conducted in these patients. 
In general, it is not easy to compare results from different studies of 
comorbidity as a prognostic and predictive factor since the eligibility criteria, study 
therapy and methods for assessment vary to a great extent. There may be good 
reasons for varying eligibility criteria (e.g. safety precautions) and study therapies 
(e.g. introduction of new compounds). However, a standard instrument for the 
assessment of comorbidity may be necessary to further gain knowledge about how to 
find the optimal therapy for the large group of patients with co-existing disorders. 
There appears to be two kinds of instruments for measurement of comorbidity in use 
today; indices like the Charlson Comorbidity Index that are easy to use – and 
instruments like the CIRS-G that records and rates all disorders. The main strength 
of the simple instruments is that they can easily be used in large, multicentre trials 
and does not require much training. Instruments like the CIRS-G are comprehensive 
and give a more detailed picture of the patient’s health status, but are time and 
resource demanding. 
 The optimal assessment of comorbidity will probably have to include a detailed 
list of all co-existing disorders and diseases, a rating of the disorder using well 
recognized rating scales and the therapy for each condition. This is the only way to 
ensure the possibility to compare results over time since the classification and 
therapy of diseases are not constant. For example, when looking at the rating of 
cardiovascular disase in the CIRS-G, one can question whether the number of 
medications today reflects the same degree of illness as when the CIRS-G manual 
was developed in 1991. E.g. the use of statins was introduced in the mid-1990s and 
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as a consequence a larger proportion of patients with cardiovascular disease are 
now treated with at least one more drug than before. 
 The optimal tool for measuring comorbidity does not exist today. To further 
develop such an instrument, large databases have to be built through an extensive, 
international collaboration. 
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Appendix A – The EORTC QLQ C30 plus LC 13 
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Appendix B – The RECIST criteria 1.0 
Malignant Disease Evaluation 
To assess objective response, it is necessary to estimate the overall tumor burden at 
baseline to which subsequent measurements will be compared.  Measurable disease 
is defined by the presence of at least one measurable lesion. 
All measurements should be recorded in metric notation by use of a ruler or 
calipers.  The same method of assessment and the same technique should be used 
to characterize each identified lesion at baseline and during follow-up.  All baseline 
evaluations should be performed as closely as possible to the beginning of treatment 
and never more than four weeks before being registered for protocol treatment. 
The term unevaluable in reference to measurability will not be used because it 
does not provide additional meaning or accuracy. 
At baseline, tumor lesions will be characterized as either measurable or non-
measurable. 
Measurable Lesions 
Lesions that can be accurately measured in at least one dimension (longest diameter 
to be recorded) as ≥ 20 mm (2.0 cm) with conventional techniques or as ≥ 10 mm 
(1.0 cm) with spiral CT scan. 
 If the measurable disease is restricted to a solitary lesion, its neoplastic nature 
should be confirmed by cytology/histology. 
Non-Measurable Lesions 
All other lesions, including small lesions [longest diameter <20 mm (2.0 cm) with 
conventional techniques or < 10 mm (1.0 cm) with spiral CT scan] and truly non-
measurable lesions. 
Lesions considered to be truly non-measurable include the following:  bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory 
breast disease, lymphangitis cutis/pulmonis, abdominal masses that are not 
confirmed and followed by imaging techniques, and cystic lesions. 
Tumor lesions that are situated in a previously irradiated area are not 
considered measurable. 
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Definitions of Response - Target Lesions 
Target lesions will be all measurable lesions up to a maximum of five lesions per 
organ and 10 lesions in total, representative of all involved organs.  Target lesions 
should be selected on the basis of their size (those with the longest diameters) and 
their suitability for accurate repeated measurements. 
The sum of the longest diameters of all target lesions will be calculated at 
baseline and reported as the baseline sum longest diameter.  This baseline sum 
longest diameter will be used as the reference by which to characterize the objective 
tumor response.  For lesions measurable in 2 or 3 dimensions, always report the 
longest diameter at the time of each assessment. 
Complete Response (CR) 
The disappearance of all target lesions.  To be assigned a status of complete 
response, changes in tumor measurements must be confirmed by repeat 
assessments performed no less than four weeks after the criteria for response are 
first met. 
Partial Response (PR) 
At least a 30% decrease in the sum of the longest diameters of target lesions, taking 
as reference the baseline sum longest diameter.  To be assigned a status of partial 
response, changes in tumor measurements must be confirmed by repeat 
assessments performed no less than four weeks after the criteria for response are 
first met. 
Progressive Disease (PD)  
At least a 20% increase in the sum of the longest diameters of target lesions, taking 
as reference the smallest sum longest diameter recorded since the baseline 
measurements, or the appearance of one or more new lesion(s). 
Stable Disease (SD) 
Neither sufficient shrinkage to qualify for partial response nor sufficient increase to 
qualify for progressive disease. To be assigned a status of stable disease, 
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measurements must have met the stable disease criteria at least once after study 
entry at a minimum interval (in general, not less than six to eight weeks).  
Definitions of Response – Non-Target Lesions 
All other lesions or sites of disease.  Measurements of these lesions are not required, 
but the presence or absence of each should be noted throughout follow-up. 
Complete Response (CR) 
The disappearance of all non-target lesions and normalization of tumor marker 
levels, if applicable.  To be assigned a status of complete response, changes in 
tumor measurements must be confirmed by repeat assessments performed no less 
than four weeks after the criteria for response are first met. 
Incomplete Response/Stable Disease (SD) 
The persistence of one or more non-target lesion(s) and/or the maintenance of tumor 
marker levels above the normal limits.  To be assigned a status of stable disease, 
measurements must have met the stable disease criteria at least once after study 
entry at a minimum interval (in general, not less than six to eight weeks).  
Progressive Disease (PD) 
The appearance of one or more new lesion(s) and/or unequivocal progression of 
existing non-target lesions. 
Symptomatic Deterioration 
Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
classified as having symptomatic deterioration. 
Evaluation of Patient's Best Overall Response 
The best overall response is the best response recorded from the start of treatment 
until disease progression/recurrence, taking as reference for progressive disease the 
smallest measurements recorded since the treatment began.  The table below 
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provides overall responses for all possible combinations of tumor responses in target 
and non-target lesions, with or without new lesions. 
 To be assigned a status of complete or partial response, changes in 
tumor measurements must be confirmed by repeat assessments performed no less 
than four weeks after the criteria for response are first met. 
 To be assigned a status of stable disease, measurements must have 
met the stable disease criteria at least once after study entry at a minimum interval 
(not less than four weeks). 
 
Overall Response for all Possible Combinations of Tumor Response 
Target Lesions Non-Target Lesions New Lesions Overall Response 
CR CR No CR 
CR Incomplete response / SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
CR = Complete Response; PR = Partial Response; SD = Stable Disease; PD = Progressive Disease 
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Purpose: To investigate the efﬁcacy and tolerability of high-dose pemetrexed as second-line chemotherapy
in small cell lung cancer (SCLC).
Patients andmethods:Patientswith veriﬁed SCLCwhohad received oneprior chemotherapy regimen, aged
18–75 years, WHO Performance Status 0–2, no clinical signs of brain metastases and measurable disease
were eligible. Patients received pemetrexed 900mg/m2 IV every 3 weeks. Four courses were planned for
all patients. Patients with relapse later than 3 months since last course of ﬁrst-line chemotherapy were
deﬁned as “sensitive”, those with relapse within 3 months as “refractory”. Toxicity was graded using the
CTCAE v3.0.
Results: 36 patientswere accrued, 34 received study treatment.Median agewas 61 (range 43–74), 18 (53%)
males and 16 (47%) females. Mean number of courses administered was 2.5. One patient (3%) had partial
response, three (9%) had stable disease and 29 (85%) progressed. One patient (3%) was not evaluable for
response. Median TTP (n=33) was 7.7 weeks (“sensitive”: 8.4 weeks, “refractory”: 5.1 weeks). Median OS
(n=34) was 17.6 weeks (“sensitive”: 22.6 weeks, “refractory”: 15.3 weeks). Of grade 3–4 haematological
toxicity, anemia was observed in 2 (6%) patients, leukopenia in 6 (18%), granulocytopenia in 9 (27%) and
thrombocytopenia in 3 (9%). Febrile neutropenia occurred in 6 (18%) patients. There were no treatment
related deaths.
Conclusion: High-dose pemetrexed monotherapy to patients with recurrent SCLC yielded moderate toxi-
t efﬁc
1
u
P
T
t
0
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. IntroductionA platinum compound in combination with etoposide is widely
sed as ﬁrst-line chemotherapy for small-cell lung cancer [1–3].
atients with limited disease (LD) also beneﬁt from concurrent
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horacic radiotherapy [4]. Response rates above 80% have been
eported in patients with LD, and 40–50% in extensive disease (ED)
2,3]. The 5-year survival is 10–26% for LD, while few patients with
D survive more than 2 years [1–3].
Despite high response rates to ﬁrst-line therapy, a majority of
atients relapse within 1 year. Palliative radiotherapy is then a
reatment option, but most patients have advanced disease and
eed systemic therapy. Reported response rates to second-line
hemotherapy of 12–25% are lower than for ﬁrst-line therapy
5–10]. However, a survival beneﬁt has been observed after
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responded to therapy (CR+PR) at evaluation 3 weeks after lastB.H. Grønberg et al. / Lu
econd-line treatment [11]. Patients who received oral topotecan
ad a signiﬁcantly longer survival than patients who received best
upportive care alone.
Important factors predicting efﬁcacy of relapse treatment are
esponse to ﬁrst-line chemotherapy, time till relapse andWHOPer-
ormance Status at relapse [5,12,13]. Patients relapsing later than 3
onths afterﬁrst-line chemotherapyare considered tohave “sensi-
ive” disease and have a better prognosis than “refractory” patients
ho progress within 3 months [5,12].
Patients with recurrent SCLC often have signiﬁcant comorbid-
ty, poor performance status and poor bone marrow function after
rst-line chemotherapy. This limits the use of second-line therapy.
onsequently, there is a need to explore the efﬁcacy of drugs that
ight offer less toxicity than the regimens used today.
Pemetrexed is an antifolate registered for the treatment of
alignant pleural mesothelioma and second-line treatment of
on-small cell lung cancer (NSCLC). The most common side effects
re myelosuppression, oral mucositis, diarrhea and skin rash [14].
rophylactic treatment with corticosteroids reduces the frequency
f rash. Since the drug is eliminated through the kidneys, a
reatinine-clearance ≥40mL/min is recommended [15]. Based on
esults from initial phase I/II trials, 500mg/m2 was deﬁned as
he standard dose [14,16]. Later, it was observed that toxicity was
educed in patients supplemented with vitamin B12 and folic acid
17].Newphase I trialswereperformedand the recommendeddose
or patients not heavily pretreated with chemotherapy was deﬁned
s 1000–1050mg/m2 provided vitamin supplementation [18,19].
Pemetrexed inhibits growth of cell lines from small-cell lung
ancer [20]. Several agents effective in the treatment of NSCLC
ave shown efﬁcacy in recurrent SCLC [8–10]. Pemetrexed has a
avorable toxicity proﬁle in second-line treatment of patients with
SCLC [21], a population comparable to patients with recurrent
CLC. In general, it is assumed to be beneﬁcial to administer as
igh a dose of chemotherapy as possible. A trial investigating the
fﬁcacy of pemetrexed 500mg/m2 (standard dose) in recurrent
CLC [22] was already initiated when we planned our study. The
im of this study was to investigate the efﬁcacy and tolerability
f pemetrexed 900mg/m2 (high-dose) in patients with recurrent
CLC.
. Patients and methods
.1. Design
The study was designed as an open, multi-center phase II trial
ndwas approved by the Regional Committee forMedical Research
thics in Central Norway, the Norwegian Medicines Agency, the
orwegian Social Science Data Services and the Norwegian Direc-
orate for Health and Social Affairs.
.2. Eligibility criteria
Eligible patients had histological or cytological proven
CLC, received one prior chemotherapy regimen (re-induction
herapy with the ﬁrst-line regimen at ﬁrst relapse was
llowed), age 18–75 years, given written informed consent,
HO Performance Status 0–2, no clinical symptoms of brain
etastases, platelets ≥100×109/L, absolute neutrophil count
ANC)≥1.5×109/L, creatinine-clearance ≥45mL/min (calculated
sing the Cockroft–Gault formula), bilirubin <1.5×ULN, ALT and
LP <3×ULN (in case of liver-metastases: <5×ULN) and measur-
ble disease according to the Response Evaluation Criteria in Solid
umors (RECIST). Pregnant or lactating women or patients with
ther active malignant disease were not eligible.
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.3. Therapy
All patients were supplemented with folic acid 0.4mg PO once
aily andVitaminB121mg IMevery9weeks, startingat least 5days
efore the ﬁrst course of chemotherapy and lasting until 3 weeks
fter the last course. Dexamethasone 4mg×2 BID (or an equiva-
ent dose of another corticosteroid) was given the day prior to, the
reatment day, and the day after every course of study treatment.
emetrexed 900mg/m2 was administered IV over 10min every 3
eeks. Four courses were planned for all patients.
Prior to each course, ANC had to be ≥1.5×109/L, platelets
100×109/L, creatinine-clearance ≥45mL/min and any grade 3–4
on-hematological toxicityhad tobe resolved. If not, treatmentwas
elayed 1 week. The dose of the following course was reduced by
5% in case of nadir ANC <0.5×109/L, a neutropenic infection or
ny grade 3–4 toxicity following the preceding course. A 50% dose
eductionwas to be performed in case of nadir platelets <50×109/L
r grade3–4mucositis. Anydose reductionsweremaintained for all
ubsequent courses. If a patient qualiﬁed for a third dose reduction,
r had a treatment-relateddelay ofmore than42days following the
receding course, the study treatment was discontinued.
.4. Endpoints and evaluation
Theprimary endpointwas overall response rates (ORR). The sec-
ndary endpoints were overall survival (OS), time to progression
TTP) and toxicity.
A baseline CT scan of the thorax and upper abdomen was
erformed within 1 week prior to chemotherapy. Hemoglobin, leu-
ocytes, ANC and platelet count were assessed on day 8 and 15
f every treatment cycle. All patients were evaluated for response
ith a CT scan 3 weeks after the fourth course of chemotherapy
earlier if progression was suspected) using the RECIST-criteria. A
T scanwasperformedevery8weeksuntil progression.All patients
ere observed for one year or until death. No central review of the
T-scans was performed. Toxicity was assessed at every visit and
as graded using the CTCAE v3.0. We estimated overall survival
nd time to progression using the Kaplan–Meier method.
.5. Statistical considerations
Patients with relapse later than 3 months after the last course
f ﬁrst-line chemotherapy were deﬁned as “sensitive”, those with
elapse within 3 months as “refractory”. A two-stage Simon design
as used to deﬁne sample size in each group using a one-sided
lpha of 10% and a power of 90% [23].
For “sensitive” patients, a rate of non-progressive disease (non-
D) of 40–60% was considered to be of clinical signiﬁcance. 18
atients were to be enrolled in the initial phase of inclusion.
f ≥8 patients showed non-PD [complete response (CR) +partial
esponse (PR) + stable disease (SD)] at evaluation 3 weeks after
he last course of chemotherapy, 28 additional patients were to be
ncluded in this group. However, enrolment was to continue until
t was possible to conclude whether the target number of patients
ith non-PD in the initial phase of enrolment was reached. The
tudy treatment would be considered worth further investigation
n this patient population if ≥23 of 46 patients showed non-PD.
For “refractory” patients, a rate of non-progressive disease of
0–25% was considered to be of clinical signiﬁcance. 21 patients
ere to be enrolled in the initial phase of inclusion. If ≥3 patientsourse of chemotherapy, 29 additional patientswere to be included
n this group. However, enrolment was to continue until it was pos-
ible to concludewhether the target number of patientswith treat-
ent response in the initial phase of enrolment was reached. The
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Table 1
Baseline patient characteristics
Sensitive patients (n=25) Refractory patients (n=9) All patients (n=34)
Age
Median (range) 61 (43–74) 65 (58-74) 61 (43–74)
Gender
Male 15 60% 3 33% 18 53%
Female 10 40% 6 67% 16 47%
WHO Performance Status
0 4 16% 1 11% 5 15%
1 14 56% 4 44% 18 53%
2 7 28% 4 44% 11 32%
Stage of disease at diagnosis
Limited disease 13 52% 1 11% 14 41%
Extended disease 12 48% 8 89% 20 59%
Asymptomatic brain metastases 6 24% 3 33% 9 26%
First-line chemotherapy
Cisplatin/Etoposide 12 48% 3 33% 15 44%
Carboplatin/Etoposide 9 36% 2 22% 11 32%
Carboplatin/Irinotecana 2 8% 2 22% 4 12%
Cyclophosphamide/Adriamycin/Vincristinb 1 4% 2 22% 3 9%
Carboplatin/Vinorelbinec 1 4% 0 0% 1 3%
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Da Carboplatin/Irinotecan was offered to patients as part of a clinical trial.
b Patients considered unﬁt for platinum-therapy were offered CAV.
c Initially misdiagnosed and treated as non-small cell lung cancer.
tudy treatment would be considered worth further investigation
n this patient population if ≥8 of 50 patients responded to therapy.
. Results
.1. Patients
Between May and October 2005, 36 patients were enrolled at
6 hospitals in Norway. Two patients never received any study
reatment andhave been excluded from the analyses; onedied sud-
enly for anunknown reasonwhile the other received radiotherapy
ecause of rapid progression.
Baseline patient characteristics are shown in Table 1. Median
ge was 61 years, 23 (68%) patients had WHO Performance Status
–1, 14 (41%) had limited disease at diagnosis, 25 (74%) had “sen-
itive” disease and 9 (26%) had asymptomatic brain-metastases,
6 (76%) had received a platinum compound plus etoposide as
rst-line chemotherapy. Two patients had received re-induction
hemotherapy with their ﬁrst-line regimen at the ﬁrst relapse. One
atient was initially misdiagnosed with non-small cell lung cancer
nd received carboplatin/vinorelbine as ﬁrst-line chemotherapy..2. Study treatment
Details are presented in Table 2. Themean number of completed
ourses was 2.5 (“Sensitive” 2.7; “refractory” 1.9). Dose-reductions
3
5
“
able 2
tudy treatment administered
Sensitive patients (n=25)
o. of courses of pemeterxed
1 5 20%
2 6 24%
3 6 24%
4 8 32%
ean no. of courses 2.7
otal no. of courses 67
o. of courses with dose-reduction 3 4%
o. of delayed courses 3 4%
ose-intensity (planned/administered dose) 98%ere performed in 5/84 (6%) of the courses due to pneumonia
efore the ﬁrst course (off-protocol, n=1) and hematological tox-
city (n=4). Four courses were delayed in three patients due to
ultiple grade 3–4 toxicity (n=1), grade 2 pneumonia not con-
idered treatment-related (n=1), suspected erysipelas (n=1) and
atients vacation (n=1). Dose-intensity was 97%.
Study-treatmentwas discontinued in 26 (76%) patients. The rea-
ons were progressive disease (n=21), non-hematological toxicity
n=2) and a grade 2 pneumonia not considered treatment-related
n=1). One patient withdrew because she did not feel the treat-
ent helped (n=1). One patient was erroneously considered to
ave progression after two courses of study treatment and started
n third-line chemotherapy.
.3. Response to treatment
One patient was not evaluable for response. Thus, response and
ime to progression was assessed in 33 patients. One patient had
R, three had SD and 29 had PD (Table 3)..4. Time to progression and survival
Median TTP was 7.7 weeks (“sensitive”: 8.4 weeks, “refractory”:
.1 weeks). Median OS was 17.6 weeks (“sensitive”: 22.6 weeks,
refractory”: 15.3) (Table 3, Figs. 1 and 2).
Refractory patients (n=9) All patients (n=34)
3 33% 8 24%
4 44% 10 29%
2 22% 8 24%
0 0% 8 24%
1.9 2.5
17 84
2 12% 5 6%
1 6% 4 5%
96% 97%
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Table 3
Response to study treatment, time to progression and overall survival
Sensitive patients (n=25) Refractory patients (n=9) All patients (n=34)
Best response to treatment
Complete response 0 0% 0 0% 0 0%
Partial response 0 0% 1 11% 1 3%
Stable disease 3 12% 0 0% 3 9%
Progressive disease 21 84% 8 89% 29 85%
Not evaluable 1 4% 0 0% 1 3%
Median time to progression (weeks) 95% CI 8.4 5.1 7.7
6.4–10.5 4.7–5.6 4.8–10.6
Median overall survival (weeks) 95% CI 22.6 15.3 17.6
10.7–34.5 7.8–22.8 8.4–26.8
Fig. 1. Time to progression for evaluable patients treated with pemetrexed 900mg/m2.
Fig. 2. Overall survival for patients treated with pemetrexed 900mg/m2 (= censored).
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Table 4
Hematological toxicity
Sensitive patients (n=25) Refractory patients (n=9) All patients (n=34)
Anemia
Grade 3 2 8% 0 0% 2 6%
Grade 4 0 0% 0 0% 0 0%
Leucopenia
Grade 3 3 12% 2 22% 5 15%
Grade 4 0 0% 1 11% 1 3%
Granulocytopenia
Grade 3 4 16% 0 0% 4 12%
Grade 4 2 8% 3 33% 5 15%
Thrombocytopenia
Grade 3 1 4% 0 0% 1 3%
Grade 4 1 4% 1 11% 2 6%
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Ro. of patients who received blood transfusion 4 16%
o. of patients who received platelet transfusion 0 0%
o. of patients with febrile neutropenia 4 16%
Primary locations forprogressionwere lung (n=14),mediastinal
ymph nodes (n=6), liver (n=6), brain (n=6), bone (n=4), pleura
n=2), neck lymph nodes (n=1), skin (n=1), kidney (n=1), adrenal
land (n=1) and spinal medulla (n=1). Eleven patients had ﬁrst
rogression in multiple locations.
.5. Toxicity
Grade 3–4 hematological toxicity is presented in Table 4: Ane-
ia was observed in 2 (6%), leucopenia in 6 (18%), neutropenia in
(27%) and thrombocytopenia in 3 (9%) patients. Blood or platelet
ransfusions were administered to 6 (18%) and febrile neutropenia
as observed in 6 (18%) patients.
Four patients had grade 3–4 non-hematological toxicity; mul-
iple toxicities (rash, mucositis, neutropenic septicaemia and
rthritis urica) (n=1), constipation (n=1), exacerbation of pityri-
sis versicolor (n=1) and rash (n=1). All adverse events resolved.
here were no treatment related deaths.
.6. Poststudy treatment
Fifteen patients received third-line and three received fourth-
ine chemotherapy. Ten patients received palliative radiotherapy.
. Discussion
Patients were enrolled until the ﬁrst 12 “sensitive” patients
ad been evaluated. Of these, one had SD and 11 PD. The num-
er of patients with non-PD was inadequate to complete stage
wo of inclusion of “sensitive” patients. At the same time, a study
nvestigating the efﬁcacy of pemetrexed 500mg/m2 in a simi-
ar patient-population [22] had stopped inclusion since too many
atients (both “sensitive” and “refractory”) had progressed during
tudy treatment. Based on the results from the study by Hanna et
l. [22] and our data, we concluded that pemetrexed monother-
py lack efﬁcacy in recurrent SCLC both at standard and at high
ose. Further, we found it unlikely to reach the target number of
esponses among “refractory” patients in order to complete phase
wo of the inclusion. Thus, our study group found it unethical to
ontinue inclusion even though only nine “refractory” patients had
een enrolled.
Previous studies have shown an ORR between 18–24%,
TP 12–15 weeks and OS 25–39 weeks following second-
ine treatment of SCLC with topotecan or CAV (cyclophos-
hamide/doxorubin/vincristin) [5–7]. More hematological toxicity1 11% 5 15%
1 11% 1 3%
2 22% 6 18%
as reported for these regimens when compared with high-dose
emetrexed, but the efﬁcacy of pemetrexed monotherapy appears
o be inferior.
Preliminary data from two recent trials support our ﬁndings.
anna et al. conducted a phase II trial inwhich 43 patients received
emetrexed 500mg/m2 every 3 weeks until a maximum of six
ourses. Only two PR’s were observed [22]. Raju et al. have pre-
ented results from a phase II trial investigating the efﬁcacy of
oth pemetrexed 500 and 900mg/m2 in recurrent SCLC [24]. The
tandard dose was administered to 38 and the higher dose to 78
atients. PR was observed in only one patient. Neither efﬁcacy nor
oxicitywas signiﬁcantly increased by the higher pemetrexed dose.
Apparently, escalating the dose of pemetrexed does not improve
he efﬁcacy in recurrent SCLC. This is consistent with ﬁnd-
ngs in recurrent non-small cell lung cancer and in locally
dvanced/metastatic breast cancer, where increased pemetrexed
oses failed to improve the efﬁcacy [25–27].
In conclusion, high-dose pemetrexed monotherapy to patients
ith recurrent SCLC yielded moderate toxicity, but limited treat-
ent efﬁcacy.
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Abstract 
Aim of the study: To investigate whether severe comorbidity was an independent 
significant prognostic factor for survival, predicted more toxicity or worse health 
related quality of life (HRQoL) in patients enrolled on a phase III trial comparing 
pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line 
chemotherapy of stage IIIB/IV non-small-cell lung cancer. 
Patients and methods: Patients were eligible for the phase III trial regardless of 
comorbidity provided they had performance status 0 - 2 and adequate 
kidney/liver/bone-marrow function. Comorbidity was assessed from hospital medical 
records using the Cumulative Illness Rating Scale for Geriatrics, toxicity was graded 
using the CTCAE v3.0 and the patients reported HRQoL on the EORTC QLQ-
C30/LC13. 
Results: Data from 402/436 of the patients enrolled on the phase III trial were 
analyzed in this study (medical records were not retrieveable for 34 patients). No 
significant associations were found between the presence of comorbidity and overall 
survival. Patients with severe comorbidity had a similar frequency of neutropenia as 
other patients (48 % vs. 42 %; p=.16), but experienced more neutropenic fevers (11 
% vs. 5%; p=.012) and deaths from neutropenic infections (3 % vs. 0 %; p=.027). 
Patients with severe comorbidity reported poorer HRQoL, but not significantly more 
deterioration of HRQoL during the treatment period. 
Conclusions: The results from our study suggest that patients with advanced 
NSCLC who have severe co-existing disorders benefit from and tolerate 
chemotherapy as well as other patients. However, these patients appear to have a 
higher risk of acquiring infections when neutropenic. 
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Introduction 
Lung cancer is one of the most common malignant diseases and the leading 
cause of cancer-deaths worldwide. Non-small-cell lung cancer (NSCLC) accounts for 
approximately 85 % of the cases and about half of the patients are diagnosed with 
advanced disease. Platinum-based chemotherapy is the recommended palliative 
therapy for these patients as it prolongs survival and improves health-related quality 
of life (HRQoL).1,2 However, many patients with significant comorbidity, especially 
elderly, do not receive such treatment.3 One reason may be concerns about negative 
side effects in terms of toxicity and deterioration of HRQoL2,4 – though this is poorly 
investigated; in clinical trials, comorbidity is seldom systematically assessed and 
reported, and elderly and patients with significant comorbidity are often 
underrepresented.5,6 
Comorbidity increases with age,7 and due to a growing population of elderly 
cancer patients, there is a need to define how patients with co-existing disorders 
should be treated. This is particularly true for lung cancer patients; the median age is 
approximately 70 years,8 and as a majority have been tobacco-smokers, a well-
known risk factor for a wide range of diseases, the presence of co-existing diseases 
is frequent.7,9,10  
Comorbidity has been identified as an independent prognostic factor for 
survival in several cancers,11,12 while the results from studies of NSCLC are not 
consistent. Whereas a negative association between the presence of comorbidity 
and survival has been demonstrated in studies of stage I9 and stage III10 and cohorts 
of mixed stages,13,14 this has not been confirmed in advanced disease.12,15,16 There 
are indications that NSCLC patients with severe comorbidity experience more 
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treatment related toxicity than other patients,13,17 but no studies have investigated the 
impact on HRQoL during chemotherapy. 
The Norwegian Lung Cancer Study Group has conducted a phase III trial 
comparing pemetrexed/carboplatin with gemcitabine/carboplatin as first-line 
chemotherapy in advanced NSCLC.18 In this report, the associations between 
comorbidity and survival, toxicity and impact on HRQoL during chemotherapy in this 
study population are presented. 
 
Patients and methods 
Approvals 
The study was approved by the Regional Committee for Medical Research 
Ethics in Central Norway, the Norwegian Medicines Agency, the Norwegian Social 
Science Data Services and the Norwegian Directorate for Health and Social Affairs. 
 
Aims 
The primary aim was to investigate whether comorbidity was an independent 
prognostic factor for survival in patients with advanced NSCLC receiving platinum-
based chemotherapy. Secondary aims were to investigate whether patients with 
comorbidity had more toxicity or deterioration of HRQoL during such treatment than 
other patients. 
 
Patient selection, study treatment, follow up, assessment of HRQoL and main 
results from the phase III study 
Eligible patients had given written informed consent, had stage IIIB (ineligible 
for curative radiotherapy) or stage IV NSCLC, WHO performance status 0-2, platelets 
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≥ 100 x 109/L, absolute neutrophil count ≥ 1.5 x 109/L, creatinine-clearance ≥ 45 
ml/min (Cockroft-Gault), bilirubin < 1.5 x ULN, ALT and ALP < 3 x ULN. All other 
comorbidities were allowed. 
Up to four cycles every three weeks of pemetrexed 500 mg/m2 plus 
carboplatin AUC=5 (Calvert) on day 1 or gemcitabine 1000 mg/m2 on day 1 & 8 plus 
carboplatin AUC=5 on day 1 were administered. Those who were ≥ 75 years had a 
25 % dose reduction based on the study-group’s experience from a previous trial 
(unpublished data). 
Patients underwent laboratory tests and completed HRQoL-questionnaires 
before each chemotherapy-cycle (weeks 0, 3, 6 & 9) and at follow-up visits every 8 
weeks from week 12-52. Toxicity was graded using the CTCAE v3.0. 
HRQoL was assessed using the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 and the Lung 
cancer specific module LC13. The QLQ-C30 measures fundamental aspects of 
HRQoL and symptoms commonly reported by cancer patients in general, the LC13 
measures symptoms commonly associated with lung cancer and its treatment. 
From May 2005 until July 2006, 436 eligible patients were enrolled at 35 
hospitals in Norway. No significant differences in HRQoL or survival were found 
between the treatment arms.18 There was more hematologic toxicity on the 
gemcitabine-arm, but not more of other grade 3-4 adverse events. Thus, for the 
present study, data from both treatment arms were analyzed jointly. 
 
Assessment of comorbidity 
The CIRS-G is an index of fourteen scales/organ systems 19,20. The severity of 
disorders on each scale is graded from 0-4. “0” indicates no problem, “1” a current 
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mild problem or past significant problem, “2” a moderate disability or morbidity 
requiring “first-line” therapy, “3” a severe/constant significant disability or an 
"uncontrollable" chronic problem and “4” an extremely severe/immediate treatment 
required/end organ failure/severe impairment in function. A manual recommends 
specific scores for common conditions.20 The total score (= sum of scores on all 
scales), the numbers of scores 3 and 4, and the severity index (= total score/number 
of categories with a score > 0) are then calculated (Table 1). 
Two physicians independently assessed comorbidity for each patient from 
hospital-charts for the last three months prior to randomization. Any differences in 
scores were discussed and the two physicians agreed on a final score. The most 
common cause of inconsistent scores was that information in the charts had been 
overlooked. Three of the authors, all physicians and specialists in oncology, did the 
assessment. 
 
Analyses and statistical considerations 
In two studies of NSCLC, patients with a severity index > 2 or a CIRS-G score 
4 had inferior survival.9,10 Thus, we defined “high severity index” as > 2 and 
“extremely severe comorbidity” as the presence of ≥ 1 CIRS-G score 4. Additionally, 
we defined “severe comorbidity” as the presence of ≥ 1 CIRS-G score 3 or 4, since it 
may be difficult to differentiate whether a disorder qualifies for a score 3 or 4.21 
Survival time was defined as time from randomization until death and was 
estimated using the Kaplan-Meier method. The log-rank test was used in the 
univariate survival-analyses to compare survival according to comorbidity-scores and 
other known prognostic factors in advanced NSCLC; performance-status (PS),22 
stage of disease,23 gender,24 smoking-history25 and baseline HRQoL14,15,26 – as well 
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as study treatment. Based on results from previous studies,15,26 appetite loss 
(baseline score > 0) and global QoL (cut-off level at 66) were defined as the most 
important prognostic baseline HRQoL-scores. Cox multivariate-analyses were 
conducted adjusting for the baseline characteristics identified as significant 
prognostic factors in the univariate survival-analyses. Toxicity-data were compared 
using Pearson’s Chi-Square and Fischer’s exact tests. 
Global QoL, fatigue, nausea/vomiting (reported on the C30) and dyspnea 
(reported on the LC13) were defined as the primary HRQoL-endpoints. Global QoL 
gives information on overall health. Nausea/vomiting and fatigue are common, 
important side effects of chemotherapy. Fatigue and dyspnea are key symptoms of 
lung cancer. 
 HRQoL scores were calculated according to the EORTC QLQ-C30 scoring 
manual. The mean scores and areas under the curves (AUC) for the first 20 
weeks were then compared. Mean scores were calculated from the reported 
values only. Missing data were imputed before calculating AUCs. Missing 
intermittent scores were replaced by the mean value of the two adjacent scores. 
Last reported value was carried forward for other missing values unless the 
patient died. In those cases, the missing values were set to zero from the time of 
death. A sensitivity test was performed using the same method for imputing 
missing intermittent values, but with the last value carried forward, even after 
death. The AUCs for each scale were compared using linear regression adjusting 
for the baseline HRQoL-scores. 
 The clinically relevant minimum difference in mean HRQoL-scores was 
defined as 10 points (on a scale from 0-100).27 Statistical significance level was 
defined as p < 0.05. 
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Results 
Patients 
Hospital medical records were not retrievable for 34 patients. Thus, 402 out of 
the 436 patients enrolled on the phase III trial were analyzed in the present study 
(Figure 1). Age distribution and the proportion of new cases of NSCLC in Norway 
accrued in each age group are shown in Figure 2A; 23 % of patients < 70 years and 
12 % of patients ≥ 70 years were enrolled (p<.001). 
Baseline characteristics for all patients and according to CIRS-G scores are 
shown in table 2. Median age of all patients was 65 years, 36 % were ≥ 70 years, 18 
% were ≥ 75 years, 58 % men, 79 % had PS 0-1 and 29 % stage IIIB. The baseline 
characteristics were well balanced between the patients with high and low severity 
index. There were more elderly, males and stage IIIB among the patients with severe 
comorbidity than among those with less comorbidity. 
 
Study treatment 
 When comparing patients with and without severe comorbidity, there were no 
significant differences in the mean number of chemotherapy cycles administered (3.2 
vs. 3.5: p=.05) or the proportion who completed all four cycles (65 % vs. 73 %; 
p=.08). Fewer patients with severe comorbidity completed four cycles without delays 
(46 % v 59 %; p=.008), but those who completed all cycles did not have more dose 
reductions (29 % v 35 %; p=.17) (Table 2). Fewer of the patients with severe 
comorbidity received second-line systemic therapy (27 % v 26 %; p=.04) or post-
study radiotherapy (35 % v 48 %; p=.01). 
There were no differences in study-treatment or post-study therapy depending 
on the presence of extremely severe comorbidity or a high severity index. 
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Comorbidity 
The distributions of the total CIRS-score and the severity indices are shown in 
figure 2B & C. The median total CIRS-G score was 7 (range 0-17). Only three 
patients had no comorbidity, 8 % had no CIRS-G scores > 1, 49 % had severe 
comorbidity (≥ one CIRS-G score 3-4), 9 % had extremely severe comorbidity (≥ one 
CIRS-G score 4) and 15 % had a high severity index (> 2). 
Most CIRS-G scores 3 and 4 were registered on the respiratory (25 %), 
vascular (10 %) and heart (10 %) scales (Figure 2D); 68 % of the patients with 
severe comorbidity had disorders on these scales only. 
 
Survival 
There were no significant differences in survival when comparing patients with 
and without severe comorbidity (6.9 v 8.1 months; p=.34), with and without extremely 
severe comorbidity (6.7 v 7.7 months; p =.88) and patients with a high severity index 
with those having a low (8.4 v 7.4 months; p=.76). Nor did comorbidity influence 
survival among the patients with PS 2 or age ≥ 75 years. 
PS (p=.001), gender (p=.02), baseline global QoL (p=.004) and appetite loss 
(p=.006) were significant prognostic factors in the univariate survival analyses. 
According to the multivariate survival analyses, PS (0-1 v 2: HR .74; 95 % CI .56 - 
.96) and gender (women v men: HR .76; 95 % CI .61 - .96) but none of the 
comorbidity-scores were significant prognostic factors (Table 3).  
 
Toxicity 
The patients with severe comorbidity developed significantly more often grade 
3-4 thrombocytopenia than those with less comorbidity (46 % v 36 %; p=.03), but did 
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not experience more thrombocytopenic bleedings (3 % vs. 4 %; p=.65). The 
frequency of grade 3-4 neutropenia was comparable (48 % vs. 42 %; p=.16) whereas 
significantly more neutropenic fevers (12 % vs 5%, p=.01) and all deaths from 
neutropenic infections  (3 % vs 0 %, p=.03) were observed among patients with 
severe comorbidity (Table 4). When looking at the subgroup of patients < 75 years, 
the same pattern of differences in toxicity depending on the presence of severe 
comorbidity were observed. 
The patients with severe comorbidity who developed neutropenic fevers had 
disorders on the following CIRS-G scales: Heart (n=8), vascular (n=7), respiratory 
(n=11), genitourinary (n=1) and psychiatric (n=1). The patients who died from 
neutropenic infections had severe comorbidity in the respiratory (n=4) and the 
vascular system (n=1). 
Extremely severe comorbidity or a high severity index did not predict more 
grade 3-4 adverse events. 
 
Health related quality of life 
Compliance of the HRQoL-questionnaires during the first 20 weeks was 88 %, 
and was similar in all subgroups. At all time points for assessment of HRQoL, the 
mean scores indicated a poorer HRQoL in patients with severe comorbidity 
compared to the other patients (Figure 3). However, the difference only exceeded 10 
points at one time point (week 12) and only on three of four scales (global QoL, 
fatigue and dyspnea).  
When comparing AUCs, the patients with severe comorbidity had significantly 
worse global QoL (p=.01), more fatigue (p=.001) and dyspnea (p=.01), whereas 
nausea/vomiting was comparable to what the patients with less comorbidity reported 
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(p=.31). The sensitivity tests confirmed the difference for global QoL (p=.002), but not 
for fatigue (p=.48), nausea/vomiting (p=.86) or dyspnea (p=.28). 
On the other HRQoL-scales, there was a trend towards worse physical and 
role functioning among the patients with severe comorbidity. Extremely severe 
comorbidity or a high severity index did not predict significant differences in HRQoL 
during study treatment. 
 
Discussion 
None of the comorbidity-scores were significant prognostic factors for survival 
in our study population. This contrasts the results from previous studies of patients 
with localized disease and mixed cohorts of NSCLC-patients,9,10,12-14 but are 
consistent with studies of patients with metastatic disease12, elderly (≥ 70 years) 
receiving non-platinum chemotherapy15 and elderly (≥  65 years) receiving platinum-
chemotherapy.16  
A possible explanation why comorbidity does not appear to be a prognostic 
factor in advanced NSCLC, is given by Read et al.12 They analyzed patients with 
breast, colon, lung and prostate cancer and found that the influence of comorbidity 
on survival is relative to the prognosis of the malignant disease. Whereas comorbidity 
was a prognostic factor for survival in patients with a long life expectancy, this was 
not the case in cohorts with a poor prognosis - such as metastastic lung cancer. 
These patients seem to die from their cancer before other disorders worsen enough 
to influence survival. 
Overall, there was no association between comorbidity and clinically relevant 
toxicity from the chemotherapy. However, patients with severe comorbidity appeared 
to acquire more fevers when neutropenic and it is worth noticing that all patients who 
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died from neutropenic infections in our trial had such disorders – mainly in the 
cardiovascular and respiratory systems. 
The results from other analyses of toxicity in relation to comorbidity are not 
consistent,13,16,17 possibly due to small sample sizes and differences in 
pharmacological profile and intensity of the chemotherapy administered. However, 
the association between comorbidity and the risk of infection in lung cancer patients 
has been demonstrated in a previous trial,13 and studies of patients with several 
types of cancers have shown that comorbidity increases the risk for complications 
from neutropenic infections.28,29 From a clinical point of view it seems reasonable that 
patients with cardiovascular and respiratory disease may have a higher risk of 
developing infections when neutropenic. Since 40 % of our study population had 
such disorders, withholding chemotherapy from these patients does not seem to be 
an option to avoid neutropenic complications among a few. Prophylactic antibiotics 
and/or granulocyte colony stimulating factors may, however, be appropriate and 
beneficial. 
The results from the HRQoL-analyses have to be interpreted with caution. 
When looking at the mean scores, the patients with severe comorbidity reported 
poorer HRQoL and they had slightly more deterioriation than the patients with less 
comorbidity. However, the differences in mean scores were only clinically relevant (> 
10 points) at one time point (week 12). Statistically, there were significant differences 
in the primary AUC-analyses for three of the four dimensions defined as the primary 
HRQoL-endpoints, whereas the sensitivity AUC-analyses confirmed these findings 
only for one dimension. Overall, we find that the differences in deterioration of 
HRQoL were not large enough to deny patients with severe comorbidity life-
prolonging chemotherapy. There are no entirely relevant reports for comparison, but 
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in a study of head and neck cancer, patients with severe comorbidity had inferior 
HRQoL before, but not after radiotherapy.30 
There are some possible limitations to our study. All comorbidities may not 
have been recorded in the hospital medical records, and some patients may have 
been considered ineligible for the study due to significant comorbidity despite broad 
inclusion criteria. However, the prevalence of severe comorbidity in our population is 
comparable to what has been registered in other studies of NSCLC-patients.7,15 The 
sample size is large, and we find that the study population is quite representative for 
the patients seen in the everyday clinic; a large proportion had PS 2, and even if 
elderly are underrepresented also in our trial, more than one third was > 70 years. 
 The CIRS-G is one of the most commonly used instruments for measuring 
comorbidity, is comprehensive and has good inter-rater and test-retest reliability21. 
Compared with the Charlson index, the most popular instrument for measuring 
comorbidity, the CIRS-G is more sensitive since it includes assessment of non-lethal 
conditions. Some of these may be especially important for cancer patients receiving 
chemotherapy - such as liver and renal dysfunction. Another reason for using the 
CIRS-G, was that in two studies of NSCLC, CIRS-G scores but not Charlson scores 
were significant prognostic factors.9,10 
In conclusion, comorbidity was not a significant prognostic factor for survival in 
our study population. In general, the patients with severe comorbidity did not 
experience more clinically relevant toxicity or more deterioration of HRQoL than other 
patients, but they may have a higher risk for infections when neutropenic. These 
findings suggest that patients with advanced NSCLC who have co-existing disorders 
benefit from and tolerate platinum-based chemotherapy as well as other patients. 
This is, however, the first study of the influence of comorbidity assessed using the 
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CIRS-G on a larger scale in patients with advanced NSCLC receiving platinum-based 
chemotherapy. Thus, the results should be interpreted with caution and need 
confirmation. 
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